RUSNANO News Mon, 29 May 2017 08:09:57 +0300 Leading European Provider of Package Water Treatment Solutions Lenntech Approved Products of RUSNANO’s Portfolio Company MEMBRANIUM <p>Lenntech, a major international engineering company based in Holland, has been testing membrane filters produced by MEMBRANIUM (JSC&nbsp;RM&nbsp;Nanotech) for over half a year and confirmed their high quality. Lenntech put the RUSNANO&rsquo;s portfolio company on the list of approved manufacturers of membrane elements for reverse osmosis (RO), ultrafiltration (UF), nanofiltration (NF). Professional consultants of Lenntech Engineering Center will use MEMBRANIUM&rsquo;s top grade products in their water treatment solutions.</p> <p>&ldquo;We work with many foreign companies, and it is rather important for us that an industry&rsquo;s major player like Lenntech approves our products. We are planning to develop and enhance partnership both with Lenntech&rsquo;s European branches and its reopened offices in other regions to promote mutually beneficial relationship and expand into new markets together,&rdquo; says <strong>Denis Makienko</strong>, CEO at RM&nbsp;Nanotech.</p> Wed, 9 Mar 2016 12:00:00 +0300 PET-Technology, RUSNANO’s Portfolio Company, Opened Nuclear Medicine Center in Yekaterinburg <p>The opening ceremony of the Positron Emission Computed Tomography (PET/CT) Center of PET-Technology, RUSNANO&rsquo;s portfolio company, took place in Yekaterinburg. The event was attended by the Governor of the Sverdlovsk Region <strong>Evgeny Kuivashev</strong>, Deputy Chairman of RUSNANO <strong>German Pikhoya</strong>, Managing Director for the Investment Activity of RUSNANO <strong>Olga Shpichko</strong>, Managing Director for Regional Policy and Interaction with Government Bodies and the Federal Assembly of RUSNANO <strong>Dmitry Krinitsky</strong>, Investment Director of RUSNANO <strong>Andrei Putilov</strong>, First Deputy Chairman of the Government of the Sverdlovsk Region <strong>Vladimir Vlasov</strong>, and Minister of Health of the Sverdlovsk Region <strong>Igor Trofimov</strong>.</p> <p style="text-align: center;"><img alt="PET-Technology, RUSNANO’s Portfolio Company, Opened Nuclear Medicine Center in Yekaterinburg" src="/upload/images/news/2016-06-29_PET_Ekaterinburg_02.jpg" /></p> <p>After a ceremonial tour of the PET Center, there was a meeting attended by the Governor of the Sverdlovsk Region <strong>Evgeny Kuivashev</strong> and Deputy Chairman of RUSNANO <strong>German Pikhoya</strong>. The meeting was focused on the discussion of practical application of the high-tech medical services for diagnostics and treatment of oncology diseases of the people of the Sverdlovsk Region. The meeting participants also discussed the development strategy of the Regional Positron Emission Computed Tomography (PET/CT) Center.</p> <p>Following the meeting, the parties agreed to increase the number, quality and availability of radioisotope diagnostics and treatment for the residents of the Sverdlovsk Region. Furthermore, the agreements were reached for further promotion of the modernisation and retrofit of the PET/CT Center in Yekaterinburg, as well as the establishment of a working group under the Government of the Sverdlovsk Region with the participation of the Ministry of Health of Sverdlovsk Region and the authorities and organisations concerned. The Ministry of Health of the Sverdlovsk Region in cooperation with the Regional Compulsory Medical Insurance Fund will work on increasing the quota for diagnostic procedures in the PET/CT Center. Today, the Regional Compulsory Medical Insurance Fund budget covers the costs of medical tests for up to 6,000 patients annually. PET-Technology will develop and as of September 2016 will start to implement a Training Programme for Radiologists with the possibility of internship in the Nuclear Medicine Center in Yekaterinburg.</p> <p>&ldquo;The opening of the PET Center in Yekaterinburg is another important step in our strategy to create a network of nuclear medicine centers across Russia. Our top priority task is to help the greatest number of people suffering from oncology diseases. The successful treatment of oncology patients depends on the quality of diagnostics. The Positron Emission Computed Tomography allows us to both accurately localise the tumour and also to determine the response of cancerous tissues to the treatment. The opening of the Center will improve the quality of patients&rsquo; treatment and thus save lives,&rdquo; said Deputy Chairman of RUSNANO <strong>German Pikhoya</strong>.</p> <p>&ldquo;The Sverdlovsk Region has managed to achieve significant progress in the development of high-tech medical care. In terms of the level of funding in this sphere, we are ranked second in Russia after Moscow, which gives us an opportunity to conduct large-scale work in the fight against the most dangerous diseases, including cancer. In 2015, the high percentage of early detection of diseases and the effectiveness of treatment allowed the Sverdlovsk Region to become one of few regions in Russia that saw the reduction in the cancer mortality rate. I am sure that by opening the PET Center today we are taking another important step in the development of high-tech medicine. We will improve the quality and effectiveness of the treatment of oncology patients, thus healing and maintaining the health of thousands of the Ural people&rdquo;, said <strong>Evgeny Kuivashev</strong>.</p> <p>Oncology diseases are one of the two major causes of death in Russia. Today, the most modern and accurate diagnostics tool for oncology diseases is the PET/CT scanning. This technology gives us an opportunity to accurately define a treatment strategy for diseases at the earliest stages, control its effectiveness and exclude unnecessary and often expensive treatment methods.</p> <p>The network of PET/CT Centers allows us to make this type of diagnostics accessible for the citizens of many Russian regions.</p> Wed, 29 Jun 2016 12:00:00 +0300 Crocus Nano Electronics and Angstrom Biotechnologies Inc. Enter Collaboration for the Biosensors Technology <p>RUSNANO&rsquo;s Portfolio Company&mdash;Crocus Nano Electronics, the only Russian microelectronics manufacturing facility on 300 mm wafers and leader in manufacturing of magnetic semiconductor solutions, and Angstrom Biotechnologies Inc., a developer of biological sensors, signed memorandum of understanding. Parties agreed on cooperation for the production of biosensors and lab-on-a-chip for rapid diagnosis of diseases and infections.</p> <p>Companies identified further scope of works within cooperation boundaries, divided in three phases: development of process technology using Crocus Nano Electronics manufacturing facility, technology qualification and mass production of bio-sensors, developed by Angstrom Biotechnologies Inc. Companies expect to implement a plan of work until the end of 2018.</p> <p>&ldquo;Mass production of bio-sensors is a unique project and open a great opportunities for russian electronics and biotechnology industries&rdquo;, said <strong>Oleg Syutin</strong> CEO of Crocus Nano Electronics. &ldquo;Our project aims to localization of innovation technologies in Russia and provide to Russian and world-wide markets affordable devices for rapid diagnosis.&rdquo;</p> <p>&ldquo;Angstrom Biotechnologies Inc. bio-sensors based on molecular diagnostics and microarray technologies&rdquo;, said <strong>Igor Ivanov</strong>, president of Angstrom Biotechnologies Inc. &ldquo;Crocus Nano Electronics is a reliable partner for mass production of bio-chips and advancement on the market medical devices.&rdquo;</p> <p>Crocus Nano Electronics manufacturing facility include all required equipment for production and metrology of biosensors and lab-on-chip. Parties expect to apply bio-sensors for medicine diagnosis and agricultural development.</p> <p>According to various estimates, global market of biological diagnosis is one of the fastest growing segments of innovation electronics market. Global biological diagnosis market is &gt;$50 billion in 2015 and estimated to be &gt;$80 billion by 2022.</p> Wed, 27 Apr 2016 12:00:00 +0300 Chad Mirkin Has Been Announced RUSNANOPRIZE Laureate in 2016 <p>In 2016 <a href="" target="_blank">RUSNANOPRIZE Nanotechnology International Prize</a> was awarded to <a href="" target="_blank"><strong>Dr. Mirkin</strong></a> for the development of three-dimensional nucleic acid nanostructures called Spherical Nucleic Acids (SNAs) that are enabling technological advances in biological and medical diagnostics and pharmaceutical development. Nanosphere, Inc.&mdash;awarded for being the first in achieving successful commercialization of three-dimensional nucleic acid nanostructures (Spherical Nucleic Acids, SNAs) in production of Verigene&reg; System instrumentation and many other medical, pharmacological, and biotechnological materials and devices based on SNAs. The prize solemn award ceremony was held within the frameworks of Open Innovation Forum.</p> <div class="img"><img alt="Chad Mirkin Has Been Announced RUSNANOPRIZE Laureate in 2016" src="" /> <p>Dr. Chad Mirkin (in the center) has been announced RUSNANOPRIZE Laureate in 2016</p></div> <p>Essentially, Dr. Mirkin has taught the world that organizing nucleic acids, the most important class of molecules ever studied, into highly oriented, densely packed spherical materials can dramatically change the fundamental chemical and physical properties of such structures and make them extraordinarily useful in the areas spanning biomedicine, pharmacology, and biotechnology, including clinical diagnostics and intracellular gene regulation and immunomodulation. As both the top most cited chemist and nanomedicine researcher in the world, Chad Mirkin has clearly distinguished himself academically, but the ultimate value of his work is being proven by its impact on business and society as well as life itself. Dr. Mirkin&rsquo;s discoveries and inventions, particularly those involving SNAs (nanomaterials which are typically comprised of nanoparticle cores and densely functionalized and highly oriented nucleic acid shells), are rooted in basic science advances, but yet are igniting change across a number of industries from the life sciences to health care.</p> <p>Dr. Mirkin is the inventor on over 1,000 patent applications (288 issued) worldwide. His SNA inventions are at the core of product development at Nanosphere (recently acquired by Luminex) and form the basis of a patent portfolio ranked by 1790 Analytics as number two in the world across all industries behind that of only Hewlett Packard Company. His work and leadership have helped to build Northwestern University into one of the largest nanotechnology centers in the world. Northwestern was selected as one of the six nanoscale science and engineering centers funded by the National Science Foundation and as one of eight nanocancer centers funded by the National Cancer Institute. It should come as no surprise that funding for the Institute now exceeds $800 million, and the companies Mirkin has founded (Nanosphere, AuraSense, AuraSense Therapeutics, and NanoInk) have already garnered over $700 million in private and venture capital from some of the top firms in the industry. To quote Sir Fraser Stoddart, &ldquo;A century ago if you were an artist or writer, Paris was a magnet drawing people. Today, Northwestern is the magnet drawing people in nanotechnology.&rdquo; Mirkin has been the driving force to help make this happen.</p> <p><strong>In 2016 RUSNANOPRIZE is sponsored by Otkritie Financial Corporation Bank.</strong></p> Wed, 26 Oct 2016 12:00:00 +0300 RUSNANO’s Profit More Than Doubled for the Second Consecutive Year <p>RUSNANO&nbsp;Group consisting of JSC RUSNANO and its consolidated subsidiaries (including RUSNANO&nbsp;MC&nbsp;LLC) announced its 2015 financial performance in accordance with International Financial Reporting Standards (IFRS) confirmed by an independent auditor.</p> <p>RUSNANO&nbsp;Group achieved a total comprehensive income of RUB&nbsp;17&nbsp;bln. The equity of the Group increased by the same amount.</p> <div class="img"><img alt="Total Comprehensive Income" src="/upload/images/news/2016-03-22_MSFO_01_ENG.jpg" /> <p>Total Comprehensive Income</p> </div> <p>The financial assets value (RUSNANO&rsquo;s portfolio) rose by 23 persent to over RUB&nbsp;138&nbsp;bln. In particular, the fair value of the investment portfolio went up by RUB&nbsp;16.8&nbsp;bln and its substantial growth reached 53 persent compared to 10 persent a year earlier. At the same time, the effect of changes in foreign exchange rates decreased from 90 persent to 47 persent.</p> <p>In view of the specific character of investment cycles, the increase in the fair value of the portfolio is the result of the company&rsquo;s performance not only in 2015, but also for the previous five years.</p> <div class="img"><img alt="Value of the Investment Portfolio" src="/upload/images/news/2016-03-22_MSFO_02_ENG.jpg" /> <p>Value of the Investment Portfolio</p> </div> <p>Group&rsquo;s total assets value increased by 18.6 persent and reached RUB&nbsp;227.7&nbsp;bln.</p> <p>In 2015, Group&rsquo;s income rose by 6 persent and amounted to RUB&nbsp;7.2&nbsp;bln. RUSNANO received RUB&nbsp;6.9&nbsp;bln from its portfolio companies; the amount includes income from sale of the shares in their capital and return of the granted loans.</p> <div class="img"><img alt="RUSNANO Group's Income" src="/upload/images/news/2016-03-22_MSFO_03_ENG.jpg" /> <p>RUSNANO Group&rsquo;s Income</p> </div> <p>Herewith RUSNANO continues to fulfill its first priority commitments of a key national institution for the development of advanced nanotechnology industries. In 2015, the Group invested RUB&nbsp;15.8&nbsp;bln in the development of its portfolio companies. The observed investment reduction compared to 2014 is due to the investment facility improvements implemented by RUSNANO, the end of the active stage of the primary projects financing and the company&rsquo;s transition to direct investment funds approach.</p> <p>The amount of operating expenses of RUSNANO remained at the previous period&rsquo;s level of RUB&nbsp;5.6&nbsp;bln. Along with the increase in the portfolio&rsquo;s fair value, this fact directly indicates the efficiency of the management.</p> <p>In 2015, RUSNANO fulfilled its obligations on the repayment of borrowings (under state guarantees) to the creditors (RUB&nbsp;30.9&nbsp;bln in total, including those on direct amount of borrowings and related interests).</p> Wed, 23 Mar 2016 12:00:00 +0300 RUSNANO’s Subsidiary Sells Its Stake in American Company Tobira <p>A subsidiary of RUSNANO, RusnanoMedInvest, withdraws from the capital of Tobira Therapeutics, a company developing drugs for the treatment of liver diseases, inflammatory diseases, fibrosis, and HIV infection. The buyer is Allergan, one of the world&rsquo;s largest pharmaceutical companies.</p> <p>&ldquo;We are satisfied with the results of the largest transaction on the global pharmaceutical market. Its results confirm that we have correctly identified life science as a sphere for investment. We will use our proceeds from this transaction, inter alia, for creation of &lsquo;Big Pharma&rsquo; in Russia,&rdquo; said Chairman of the Board of MC RUSNANO <strong>Anatoly Chubais</strong> commenting on the transaction.</p> Wed, 21 Sep 2016 12:00:00 +0300 RUSNANO Proceeds to Sell Its Share in Novomet <p>RUSNANO announces the start of the open competition for the search for a buyer of its share in the portfolio company Novomet. The minimum price of the block (30.76%) determined by independent assessment is 7.5 billion rubles.</p> <p>Novomet specialises in innovation technologies, from the development of new types of oil extraction equipment to supervising and selecting oil well equipment. The company&rsquo;s main products are electric submersible centrifugal pumping plants. They are some of the best on the world market in terms of reliability and energy consumption, especially when extracting oil in complex deposits and offshore.</p> <p>RUSNANO joined the project in 2011, having invested nearly 4 billion rubles. During this period, Novomet became one of the biggest companies in its segment, ranking second in terms of market share in Russia (20%) and seventh in the world (2.3%).</p> <p>The technological innovation of the project is the use of protective and functional nanostructured coatings of tungsten carbide, with titanium and aluminium oxide, chromium and molybdenum treatment. As a consequence, the energy consumption of Novomet pumps is 20-30% lower than their equivalents and their corrosion and hydroabrasion resistance parameters are 1.5-2 times higher.</p> <p>The company supplies products and renders services to a wide range of Russian and foreign oil companies in 15 countries. Service centres of the company operate in more than 10 countries: USA, Argentina, Ecuador, Romania, Iraq, Kuwait, Indonesia, Colombia, the UAE and Egypt, Azerbaijan, Kazakhstan. In 2015 nearly 40% of the company&rsquo;s proceeds were accounted for by non-former-USSR countries.</p> <p>The results of the open competition sale procedure will be announced on August 26, 2016 at 12 midday. The main criterion in choosing the winner will be the price offered for the block of shares owned by RUSNANO. The ability of the purchaser to successfully develop the project in cooperation with other shareholders will also be taken into account.</p> Wed, 20 Jul 2016 12:00:00 +0300 Novosibirsk Plant Liotech Expands the Sales Geography <p>New export operations and the company&rsquo;s expansion in the domestic market indicate that Liotech (Novosibirsk), company producing innovative lithium-ion batteries, is emerging from the crisis. Information about its close-down was disproved.</p> <p>At the end of January, the second consignment of trolley buses with increased operating range was shipped to Z&aacute;rate, Argentina. The distinctive feature of these vehicles produced by Trolza plant is the installed lithium-ion accumulators manufactured by Liotech. The core material of the enhanced accumulators is nanostructured lithium-iron-phosphate (LiFePO4). Such power storage devices are durable, highly stable and have a relatively low price, that is 10% lower than foreign analogues.</p> <p>In addition, as a part of Liotech and Trolza cooperation, a large consignment of trolley buses with increased operating range will be shipped in the nearest future for use in Southern Russia.</p> <p>&ldquo;At this stage, the accumulator assembly is carried out on-site; in other words, we manufacture finished products. Such provision of finished products is a new chapter in the company&rsquo;s history, which corresponds to the company&rsquo;s strategy to transfer the plant from cells production to release of finished battery banks and power storage devices. They are suitable to trolley buses with increased operating range, as well as electric buses and commercial electric vehicles,&rdquo; said <strong>Valery Yarmoshchuk</strong>, CEO, Liotech-Innovations Ltd.</p> <p>In addition, Trolza placed a new order at Liotech to develop new accumulators LFP-170 with decreased capacity and enhanced performance. The contract requires supply of 34 SKD sets of LIAB (Lithium-ion accumulator batteries with DCS and thermostating). At this moment, the documentation for this product, which is scheduled for release at the end of May, 2017, is being developed.</p> <p>Also, Liotech supplies the energy market. Thus, another RUSNANO portfolio company recently launched the hybrid electric power plant (AHEP) in the village of Menza, Trans-Baikal Territory, Russia. AHEP consists of solar modules of 120kW in total power, and two diesel generators of 200kW each. The accumulator cells for the power storage device with 300kWh capacity produced by Liotech were used for the electric power plant development. As planned, in 2017, Hevel will build two more hybrid electric power plants in the Trans-Baikal Territory, Russia, where Liotech power storage devices can also be used as a completely finished containerized product, including all electronic and control systems (the supplier&rsquo;s choice will be defined upon the tender). The latest plant&rsquo;s innovations will be used for Liotech power storage devices with a full quality assurance.</p> <p>Furthermore, Russian producers of commercial transport vehicles inquire delivery of LIAB sets both for electric motor vehicles, electric buses, and special equipment. At this moment, the finished solutions for other specialized machinery are also being developed.</p> Wed, 1 Feb 2017 12:00:00 +0300 Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences <h5>Exclusive use of Selecta&rsquo;s Synthetic Vaccine Particles (SVP&trade;) platform technology provided to Spark Therapeutics for co-administration with up to five gene therapy targets, including FVIII for hemophilia A.&nbsp;SVP may enhance gene therapies by enabling repeat dosing and mitigating other potential immune responses to an AAV capsid.</h5> <p>Spark Therapeutics (NASDAQ:ONCE) and&nbsp;Selecta Biosciences, Inc.(NASDAQ:SELB) today announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta&rsquo;s proprietary Synthetic Vaccine Particles (SVP&trade;) platform technology for co-administration with gene therapy targets, including FVIII for hemophilia A, as well as exclusive options for up to four additional undisclosed genetic targets.</p> <p>Selecta&rsquo;s immune tolerance SVP, including SVP-Rapamycin, is an investigational technology intended to suppress the formation of neutralizing antibodies to an adeno-associated virus (AAV) capsid when used in combination with gene therapies, without altering the therapeutic profile of the gene therapy. Neutralizing antibodies form in response to an initial administration of an AAV gene therapy and prevent effective subsequent usage. The potential ability to re-dose a gene therapy may be beneficial where a patient has not achieved a sufficient therapeutic expression of the transferred gene in the initial dose.</p> <p>&ldquo;Selecta&rsquo;s nanoparticle technology, which is undergoing preclinical testing in gene therapy, may prevent formation of neutralizing antibodies, and thus potentially enable re-dosing up to an optimal therapeutic profile by extending the reach of gene therapy to diseases that require higher doses or more extensive transduction of target cells than may be achieved through one-time dosing,&rdquo; said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. &ldquo;Importantly, if proven successful, the co-administration of Selecta&rsquo;s technology with a gene therapy may enable repeat dosing of AAV gene therapies in both adults and pediatric patients, potentially minimizing the risk of a T-cell immune response to the capsid.&rdquo;</p> <p>&ldquo;Gene therapy is a core area of focus for Selecta; one that we believe could benefit profoundly from our immune tolerance SVP technology platform,&rdquo; said Werner Cautreels, Ph.D., president, CEO and chairman of Selecta. &ldquo;We are excited about this license agreement with Spark Therapeutics, a recognized gene therapy leader, which accelerates the application of our SVP platform in gene therapy. Our preclinical studies in this field, together with the clinical data we have generated with SEL-212 in gout showing prevention of anti-drug antibodies, suggest that the application of our immune tolerance SVP technology to biologic therapies may greatly benefit patients with life-threatening diseases who currently lack adequate treatment options due to the occurrence of undesired immune responses.&rdquo;</p> <p>Subject to the terms of the agreement, Spark Therapeutics will make an initial&nbsp;$10 million&nbsp;cash payment to Selecta and purchase&nbsp;$5 million&nbsp;of Selecta&rsquo;s common stock. Within 12 months of the agreement&rsquo;s signing, Spark Therapeutics has agreed to pay Selecta an additional&nbsp;$5 million&nbsp;in cash and to purchase&nbsp;$10 million&nbsp;of Selecta&rsquo;s common stock. Selecta will be eligible for up to&nbsp;$430 million&nbsp;in milestone payments for each target, with up to&nbsp;$65 million&nbsp;being based on Spark Therapeutics&rsquo; achievement of specified development and regulatory milestones and up to&nbsp;$365 million&nbsp;for specified commercial milestones. In addition, Spark Therapeutics will pay Selecta tiered mid-single to low-double-digit royalties on worldwide annual net sales of any resulting commercialized gene therapy.</p> <p>The terms of this agreement do not apply to Spark Therapeutics&rsquo; ongoing investigational development programs in inherited retinal diseases (IRDs), including voretigene neparvovec for the treatment of&nbsp;RPE65-mediated IRD and&nbsp;SPK-7001&nbsp;for choroideremia. This agreement does not impact Spark Therapeutics&rsquo; ongoing Phase 1/2 trial of&nbsp;SPK-9001&nbsp;in hemophilia B in collaboration with Pfizer or its planned&nbsp;Phase 1/2 trial of&nbsp;SPK-8011&nbsp;in hemophilia A.</p> <p>Selecta independently is applying its SVP technology to its own proprietary gene therapy programs. Selecta has obtained an exclusive license from Massachusetts Eye and Ear to Anc80, an&nbsp;in silico-designed gene therapy vector, for Methylmalonic Acidemia and has options for additional pre-defined indications. Additionally, Selecta is advancing a proprietary gene therapy program for Ornithine Transcarbamylase Deficiency.</p> Tue, 6 Dec 2016 12:00:00 +0300 RUSNANO Group and the Russian Export Center to Help Enterprises of the Russian Nanoindustry to Enter Global Markets <p>RUSNANO Group and the Russian Export Center have completed a cooperation agreement. The document was signed by the Chairman of the Executive Board of Management Company RUSNANO LLC <strong>Anatoly Chubais</strong>, Chief Executive Officer of the Fund for Infrastructure and Educational Programs (FIEP) <strong>Andrey Svinarenko</strong>, and General Director of the Russian Export Center (REC) <strong>Peter Fradkov</strong>.</p> <div class="img"><img alt="RUSNANO Group and the Russian Export Center to Help Enterprises of the Russian Nanoindustry to Enter Global Markets" src="/upload/images/news/2016-05-31_REC_01_700.JPG" /> <p>From left to right: General Director of the Russian Export Center (REC) Peter Fradkov, Chairman of the Executive Board of Management Company RUSNANO LLC Anatoly Chubais, and Chief Executive Officer of the Fund for Infrastructure and Educational Programs (FIEP) Andrey Svinarenko</p></div> <p>The aim of the agreement is to provide support to Russian innovation companies as they enter foreign markets. Moreover, it is not only RUSNANO&rsquo;s portfolio companies, FIEP nanocenter residents or members of the Russian Nanoindustry Association that will be able to rely on such support but independent businesses too.</p> <p>At specialised conferences and meetings, the parties to the agreement will talk about the measures of support for the export of hi-tech products that may be provided by development institutions and public authorities of the Russian Federation. The main focus of the work undertaken by the Parties will be the promotion of Russian technology products on foreign markets.&nbsp;</p> <p>RUSNANO will compile a list of technology products competitive on the international market and oversee the interaction between its manufacturer and the Russian Export Center. The Fund of Infrastructure and Educational Programs is set to optimise the existing programs designed to stimulate demand with an understanding of the need for the promotion of nanotechnology products on foreign markets. REC will help hi-tech companies properly structure their export project and undergo all the procedures related to its registration. Furthermore, manufacturers of hi-tech products will receive assistance in the adaptation of goods for export to be in line with international standards, and will be able to participate in the support programs regarding foreign patenting as well as existing and upcoming educational projects of the Parties to the cooperation agreement.</p> <p>&ldquo;Do not limit the creation of hi-tech champions to the national market only - they need to be competitive abroad, on the world stage as well. That is why RUSNANO always sets its projects the goal of breaking out of the local market. Although the real volume of export of Russian nanotechnology products in 2015 exceeded the planned level, at 195 billion roubles compared to the planned 180 billion, I am certain that the potential is significantly greater. I believe that the signing of the agreement with REC is a vital step that will facilitate a new growth trend in the export of Russian nanotechnology products,&rdquo; noted <strong>Anatoly Chubais.</strong></p> <p>&ldquo;The development of hi-tech exports is one of the priority areas of work of the Russian Export Center, and our agreement with RUSNANO and the Fund for Infrastructure and Educational Programs will allow us to increase the support provided to exporters of hi-tech products. REC has already begun working with RUSNANO&rsquo;s portfolio companies, developing a spectrum of non-financial measures and financial support for them that involve the issues of intellectual property protection and lending funds during their export activity. I am confident that together with RUSNANO and FIEP we will be able to actively promote Russian innovations on foreign markets,&rdquo; said <strong>Peter Fradkov</strong>.</p> Tue, 31 May 2016 12:00:00 +0300 Initiating Documents on the Set Up of the Russian-Indian High Technology Private Equity Fund Signed <p><strong>Anatoly Chubais</strong>, Chairman of the Executive Board of RUSNANO, and <strong>Dr Saurabh Garg, </strong>Joint Secretary of the Indian Ministry of Finance and NIIF Director, have signed a memorandum on the set up Russian-Indian high technology private equity fund.</p> <p>The Fund Limited Partners&mdash;RUSNANO and the National Investment and Infrastructure Fund (NIIF) will invest $2&nbsp;billion in equal shares and will establish a joint management company.</p> <p>The key areas of work of the private equity fund will be the implementation of the hi-tech projects at growth stage, including dual-use technologies and defense industry products. Technology transfer will be carried out with regard to the interests of both countries in creating the production facilities and service infrastructure on their territories.</p> <p>&ldquo;I would like to express my cordial thanks to our collegues from the Government of Inida for their professionalism and constructive approach that allowed us in a timely fashion to sign a substantial document that clearly resonates with the agreement between the leaders of Russia and India to support the establishment of a joint private equity fund that was reached during the official visit of the Indian Prime Minister <strong>Shri Narendra Modi</strong> to Moscow that took place on January 24, 2015. Russia and India have enjoyed a long history of mutually beneficial cooperation in various fields. The creation of the joint private equity fund is a new stage of development of our relations in harsh global market conditions. The Fund aims to strengthen the competitive position of Russian companies and promote the export of Russian high technologies into the promising Indian market,&rdquo; <strong>Anatoly Chubais</strong> emphasized. &ldquo;We have agreed that we would be ready to increase, if necessary, the size of the Fund which is to ensure greater efficiency of the processes of funding of joint innovative projects and contribute to the creation of high-skilled jobs in both countries.&rdquo;</p> Tue, 26 Jan 2016 12:00:00 +0300 The Second Stage of the Kosh-Agach Solar Power Plant Brought on Line in the Republic of Altai <p>The second stage of the Kosh-Agach solar power plant (SPP) has been brought on line in Kosh-Agach (Republic of Altai), hereby increasing the installed capacity of the power plant up to 10 MW. The investor and the general contractor for the construction are Hevel associates (a joint venture established by Renova Group and RUSNANO). The first stage of the first Russian SPP was launched in 2014. The plant start-up command was personally given by Vladimir Putin, the President of the Russian Federation.</p> <div class="img"><img alt="Kosh-Agach solar power plant (SPP)" src="/upload/images/news/2015-12-22_Hevel_700.jpg" /> <p>Kosh-Agach solar power plant (SPP)</p> </div> <p>The first stage of the Kosh-Agach SPP carries out planned power supply to the grid since April 2015. The second stage will be entitled to merchandise at the wholesale electric power and capacity market upon completion of the maintenance check established by the law.</p> <p>Two thirds of the equipment mobilized for the construction of the plant was manufactured by Russian electrical engineering and metal working enterprises. Utility connection of the power generating facility to distribution grids of the Republic of Altai was implemented by IDGC of Siberia.</p> <p>Kosh-Agach District of the Republic of Altai is one of the most insolated places in Russia. Number of sunny days here exceeds 300 days per annum.&nbsp;</p> <p>In accordance with the agreement signed between Hevel and the Government of the Republic of Altai in May 2014, it is planned to build up to 45 MW of solar power generation facilities in the region.&nbsp;</p> <p>Solar power plant construction projects are implemented in accordance with Decree of the Government of the Russian Federation No. 449 of May 28, 2013 &ldquo;On incentive mechanism for harnessing of renewable resources at wholesale electric power and capacity market&rdquo;. The decree fixes return of investment guarantees in the field of construction of renewable power generation facilities via entering into Capacity Supply Contracts in a similar way to traditional generation facilities.</p> <p>Upon the results of competitive selection of investment projects within the scope of this program in 2013 to 2015, Hevel&rsquo;s associates plan to commission 349 MW of new solar power generation facilities in various regions of Russia in the nearest three years.</p> Tue, 22 Dec 2015 12:00:00 +0300 Solar Cell Production Site Has Been Launched at the Hevel Factory, RUSNANO Portfolio Company <p>A phased launch of main systems of the modernized process line with almost doubled capacity has been started at the factory for production of solar modules by Hevel (joint venture of Renova Group and RUSNANO) in Novocheboksarsk. The site of production of photoelectric converters (PEC) constituting a solar module has been launched before other sites.</p> <p>PEC production is the main and the most complex phase of the solar module manufacturing process. The key performed operations are silicon wafer texturing, application of layers of amorphic silicon, silver or tin oxide thereon by means of magnetrons, current pickup application. The combination of these operations leads to increase of solar energy to electricity conversion ratio.</p> <p>The applied heterostructure-based technology has been developed by R&amp;D Centre of Hevel. It combines main advantages of crystal modules (high efficiency, lack of light-induced degradation) and thin-film modules (high efficiency at raised temperatures of module operation, better perception of scattered light).</p> <p>At the same time, the commissioning of the site where the cells are assembled into solar modules is coming to its end. By the end of March, the factory specialists plan to adjust all processes and proceed to solar modules production.</p> Tue, 21 Feb 2017 12:00:00 +0300 Russian Telecommunication Will Receive Domestic Optic Fibre <h5>Optic Fiber Systems, RUSNANO portfolio company, has completed certification of its products in Russia and is ready to cover up to half of the Russian market. Prior to the factory launch, the Russian needs for optic fibre have been completely satisfied due to import.</h5> <p>In December, 2016, RUSNANO portfolio company Optic Fiber Systems jointly with Rostelecom PJSC and VNIIKP OJSC (All-Russian Research and Development Institute for Cable Industry) completed a programme of testing own-produced Russian optic fibre, as well as optic fibre cable produced using it.&nbsp; Test results demonstrate positive results, and the company&rsquo;s products have been recommended to use in Rostelecom communication networks.</p> <p>Optic Fiber Systems produces optic fibre for communication cables used by telecommunication companies for data transfer. Synthetic quartz workpieces heated and pulled out to a thickness of 0.125 mm covered by protective sheath are used for production of optic fibre.</p> <p>First domestic production of telecommunication optic fibre was launched in Saransk, the capital city of Mordovia, in September 2015. The project is implemented by RUSNANO with participation of Gazprombank and the Republic of Mordovia. Total budget is 3.5 billion roubles, where RUSNANO contributed 1.7 billion roubles.</p> <p>Leading enterprises in the industry, such as Saransk Cable-Optic, Eurocable 1, Incab, Moscable-Fujikura, Opten-Cable and T8 have already tested the samples of Russian optic fibre and have given their positive feedbacks. Successful completion of certification programme with participation of Rostelecom PJSC and VNIIKP OJSC will allow to maximally expand the scope of application when building networks in Russia in the nearest future, including within the federal project &quot;Elimination of Digital Gap&quot;.</p> <p>Optic Fiber Systems have already obtained compliance certificate for commercial optic fibre according to the key international standards MSE-Т G652D and IEC 60793-2-50, and have been certified for quality management system in compliance with GOST R ISO 9001-2015 (ISO 9001: 2015) which is a warranty of compliance of domestic optic fibre quality with the international and Russian standards.</p> <p>In Q4, 2016, the factory proceeded to commercialization of optic fibre and achieved the level of over 100 thousand kilometres of fibre per month. It comprises 50% of the factory capacity and covers 25% of demand of the total Russian market, which needs have been completely satisfied due to importing prior to the factory launch.</p> <p>According to CRU Group, consumption of optic fibre in the world was increased by 11% up to 457 million kilometres in 2016. In this context, Optic Fiber Systems have successfully implemented deliveries of optic fibre in the amount of over 300 thousand kilometres to the countries of European Union and Asia, including the top ten largest manufacturers of optic fibre communication cables in China. Currently, a series of long-term export contracts have been concluded for the delivery of optic fibre.</p> <p>&ldquo;Import substitution proclaimed as one of the priorities of development of domestic industry is a primary goal in the strategically important industry as telecommunications. The results of joint tests demonstrate that Optic Fiber Systems can participate in tenders of Rostelecom itself and the other largest communication operators in Russia among the manufacturers of optic fibre cables, and the obtained compliance certificate guaranties the quality of domestic optic fibre for cable producing factories,&rdquo; has stated Deputy Chairman of the Board of RUSNANO <strong>German Pikhoya</strong>.</p> Tue, 21 Feb 2017 12:00:00 +0300 Nominations Submission for RUSNANOPRIZE 2017 Is Opened <h5>In 2017 <a href="" target="_blank">RUSNANOPRIZE</a> shall be awarded for research conducted in the fields of nanomaterials and surface modification, as decided by the Board of the <a href="/about/fiep">Fund for Infrastructure and Educational Programs</a> and due to the Regulation of the Prize nomination field choosing procedures.</h5> <blockquote>Nominations submission period will last till July 31</blockquote> <p>&ldquo;The R&amp;D in nanomaterials and surface modification field may lead to dramatic breakthroughs affecting more than one industry or sphere, such as microelectronics, metallurgy, polymers, biomedical materials, nanoscale diagnostics and many other at the same time,&rdquo; <strong>Sergey Kalyuzhny</strong>, Adviser to Chief Executive Officer&mdash;Chief Scientist of RUSNANO Group has noticed.&nbsp;</p> <p>RUSNANOPRIZE is an annual Prize awarded in one of the following fields: Optics and Nanoelectronics; Nanomaterials and Surface Modification; Medicine, Pharmacology and Biotechnologies; Energy Efficiency and Green Technologies.</p> <p>In 2013 <strong>Anatoly Chubais</strong> and Karlsruhe Institute of Nanotechnology professor <strong>Herbert Gleiter</strong> <a href="/press-centre/news/20131101-awards-ceremony-held-for-rusnanoprize-2013"><strong>presented the award for achievements</strong></a> in research conducted in the fields of nanomaterials and surface modification to <a href="" target="_top"><strong>Robert Langer</strong></a>, the David H. Koch Institute Professor at the Massachusetts Institute of Technology, and <a href="" target="_blank"><strong>Omid Farokhzad</strong></a>, associate professor at Harvard Medical School and physician-scientist in the Department of Anesthesiology at Brigham and Women&rsquo;s Hospital. They were awarded the prize for developing nanoparticle technologies for medical applications.</p> <p>The Prize is awarded annually to researchers, scientists and developers (up to three people) being the authors of scientific-technological discovery or discoveries in the field of nanotechnologies, and to the company being the first to apply the discovery (discoveries) to mass production with the annual production output of at least $10 million and reached business success through the application of the discovery (discoveries). Financial rewards, prize symbols and honorary diploma of the Prize are awarded to inventors, scientists and developers, the authors of the R&amp;D projects or technologies implemented into production. The company that has achieved some significant commercial success due to the implementation of these technologies is awarded with an honorary diploma and a glass ball, which is a RUSNANOPRIZE symbol.</p> <p>Both Russian and foreign organizations as well as personalities, save for <strong><a href="" target="_blank">Prize Awarding Committee</a></strong> members, can nominate a researcher (researchers) for the Prize, self-nomination is also possible.</p> <h5>Applications are accepted and registered by the Prize Directorate at&nbsp;<a href=""></a> in strict compliance with the <a href="" target="_blank">Nomination Form</a>. For more details and application form, please visit <a href="" target="_blank"></a></h5> Tue, 2 May 2017 12:00:00 +0300 Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers <p>Selecta Biosciences, Inc.&nbsp;(NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has licensed LMB-100, a next-generation immunotoxin, from the&nbsp;Center for Cancer Research&nbsp;(CCR) at the NCI, part of the&nbsp;National Institutes of Health. LMB-100 contains a potent bacterial toxin that binds to mesothelin, a protein expressed in all mesotheliomas, pancreatic adenocarcinomas and a high percentage of other malignancies, including lung, breast and ovarian cancers.</p> <p>&ldquo;This marks yet another major milestone for&nbsp;Selecta&nbsp;as we execute on our strategy to enable a range of proprietary, non-immunogenic biologic therapies using our proprietary immune tolerance platform,&rdquo; said&nbsp;<strong>Werner Cautreels</strong>, Ph.D., President, CEO and Chairman of&nbsp;Selecta. &ldquo;By in-licensing this promising clinical-stage product candidate, we are extending our footprint to include oncology, where the efficacy of many biologic treatments is hampered by immunogenicity. Based on our preclinical work with NCI, we believe a combination treatment of LMB-100 and our proprietary SVP-Rapamycin may allow patients with rare, serious and aggressive forms of cancer to tolerate and benefit from multiple immunotoxin treatment cycles.&rdquo;</p> <p>CCR is in the process of completing two clinical trials of LMB-100 in patients with mesothelioma and pancreatic cancer that are intended, in part, to help define the maximum tolerated dose. For more information about these trials, call 1-800-4-Cancer (1-800-422-6237) (TTY:&nbsp; 1-800-332-8615) and/or visit&nbsp;<a href="" target="_blank"></a>. Initial data indicate that undesired antibody responses to the immunotoxin prevented most patients from receiving the intended four treatment cycles. While a precursor to LMB-100 was similarly restricted by immunogenicity despite the concurrent use of potent immunosuppressive drugs, tumor regression was observed in the only two patients who were able to receive more than two cycles of treatment. These results suggest that the mitigation of immunogenicity may enable more patients to benefit from LMB-100 therapy.</p> <p>In 2016, preclinical research under a&nbsp;Cooperative Research&nbsp;and Development Agreement between&nbsp;Selecta&nbsp;and NCI demonstrated that the co-administration of SVP-Rapamycin and LMB-100 has the potential to enable extended treatment with LMB-100 and, therefore, enhance its anti-tumor activity. Selecta&rsquo;s immune tolerance Synthetic Vaccine Particles (SVP&trade;) prevented the formation of anti-LMB-100 antibodies, allowing for the administration of repeat treatment cycles in mouse models and enabling the full beneficial effect of LMB-100 on tumors in a tumor model.&nbsp;Selecta&nbsp;and NCI are currently in discussions regarding a planned Phase 1b clinical trial to evaluate multiple cycles of this combination treatment.</p> <p>Under the terms of the license agreement, NCI will receive an upfront payment of&nbsp;$50,000&nbsp;from&nbsp;Selecta. NCI also is entitled to up to&nbsp;$9.25 million&nbsp;in payments for milestones and low single-digit royalties on worldwide annual net sales of any resulting commercialized treatment.</p> Tue, 2 May 2017 12:00:00 +0300 Agreement on Establishing Joint Russian-Chinese Investment Fund Signed <p>The document was signed by <strong>Anatoly Chubais</strong>, Chairman of the Executive Board of RUSNANO, and <strong>Fang Tao</strong>, Chairman of Zhongrong International Trust.</p> <p>At the first stage, the RUSNANO Zhongrong United Investment Fund will have $500&nbsp;mln of capital under management. The Partners of the Fund, RUSNANO Group and Zhongrong Trust International Co., LTD. (Zhongrong), will provide their equity investments in equal portions and establish a joint management company.</p> <p>The Fund&rsquo;s investment focus will be concentrated on projects in the growth stage aimed at application, development, and transfer of high technologies (related to electric power industry (including RES), oil and gas industry, as well as microelectronics and biotechnologies) to Russia. It is envisaged that investments into the projects and project companies will be effected on the territory of Russia (not less than 70&nbsp;%), China, and other countries.&nbsp;</p> <p>&ldquo;Zhongrong is one of the largest financial institutes in Asia-Pacific region that specializes in private equity and financing of large-scale innovative projects,&rdquo; emphasized Anatoly Chubais. &ldquo;Our partnership is aimed at creation of the new competitive products with perspective of their launch both in Russia, China and worldwide&rdquo;.</p> Tue, 19 Jan 2016 12:00:00 +0300 Quantenna Wins the Prestigious Global Semiconductor Alliance Award for the “Most Respected Private Semiconductor Company” a Second Consecutive Year <p>Quantenna Communications, Inc. (NASDAQ:QTNA), a leading provider of high-performance Wi-Fi solutions, announced today that it received the prestigious &ldquo;Most Respected Private Semiconductor Company&rdquo; award at the 2016 Global Semiconductor Alliance (GSA) Awards Dinner Celebration on December 8th, 2016. The semiconductor industry&rsquo;s annual event honored outstanding semiconductor companies worldwide that have demonstrated excellence through their vision, strategy, execution and future opportunity.</p> <p>The GSA identified leading semiconductor companies that have demonstrated market growth through technological innovation and exceptional business management strategies. The awards are voted by GSA&rsquo;s member companies to honor their achievements. Previously, Quantenna won the &ldquo;Start-Up to Watch&rdquo; award in 2013 and last year earned the &ldquo;Most Respected Private Company&rdquo; award. Quantenna recently completed its initial public offering and is now listed on NASDAQ; the award vote was cast prior to its IPO.</p> <p>&ldquo;GSA has been following Quantenna&rsquo;s growth for many years and recognized the company with three awards in two different categories in the last four years,&rdquo; said <strong>Jodi Shelton</strong>, President of GSA. &ldquo;GSA also congratulates Quantenna on their recent IPO and looks forward to their continued success.&rdquo;</p> <p>&ldquo;We are humbled that the GSA and our peers have again recognized Quantenna as a company that is relentlessly pushing the semiconductor Wi-Fi market,&rdquo; said <strong>Dr. Sam Heidari</strong>, Chairman and CEO at Quantenna. &ldquo;This award is the perfect ending to our journey as a private company and we look forward to writing a new chapter of our success as a public company.&rdquo;</p> Tue, 13 Dec 2016 12:00:00 +0300 RUSNANO Sells its Interest in Uralplastic-N to Strategic Investor Mondi Group <p>RUSNANO announces sale of its interest in the portfolio company Uralplastic-N&mdash;one of the leaders of the Russian polymer packaging market. RUSNANO is selling its interest to the project&#39;s strategic investor, international packaging and paper group&mdash;Mondi.</p> <p>RUSNANO joined the project in 2010. The inflow of investments allowed one of the largest Russian full-cycle plants manufacturing flexible polymer packaging to be built from the ground up in a short timeframe. Three new process technologies were implemented at the plant: the production of nanocomposites, their introduction into the composition of the film and the production of film modified with nanocomposites.</p> <p>The use of nanocomposites allows it to be recycled, reduces the number of packing layers, its thickness and weight, and considerably increases its barrier characteristics.</p> <p>The plant&rsquo;s capacity is about 1,200 tons of flexible packaging per month, which is equal to approximately 500 million pieces of packaging for finished products.</p> <p>Over the past two years, the company&#39;s revenue increased significantly and reached about 2 billion rubles in 2015. In Q1 2016 the company exceeded the target for revenue by 5% and EBITDA by 10%.</p> <p>The production facility located in the town of Aramil, Sverdlovsk Region, is fitted with unique equipment for the production of nanocomposites&mdash;the only 10-layer extrusion line in Russia for the manufacturing of highly hermetic film and an unparalleled raw material batching system. These films allow the increase of the shelf life of products without the use of preservatives. The product portfolio of the company includes a wide range of packaging for the food industry (various types of flexible packaging for dairy products, meat, fish, seafood, spices and sauces), for household and personal care products, cement and dry construction mixtures and other industrial materials.</p> <p>In the process of manufacturing its products Uralplastik-N relied on the development and increase in the use of domestic raw materials. An analysis and testing of raw materials, produced by Russian manufacturers, were conducted by the company&rsquo;s own R&amp;D-centre. Following the results of research, one changed the composition of the films produced, which allowed the replacement of imported components in a number of products by similar domestic ones without loss of quality. In 2015, the share of domestic raw materials increased to 44% as compared to 29% in 2014.</p> <p>&ldquo;The acquisition of Uralplastic supports the development of our Consumer Packaging business and strengthens our presence in the Russian consumer packaging market, complementing our existing plant in Pereslavl, near Moscow and allowing us to improve our offering to customers in this growing market,&rdquo; said <strong>David Hathorn, Chief executive of Mondi Group</strong>.</p> <p>&ldquo;I&rsquo;m proud of what we&rsquo;ve achieved with Uralplastic. It has grown significantly over the years and it now joins a reputable international company that will ensure the future success of the business,&rdquo; said <strong>Alexey Goncharov, co-owner of Uralplastic-N.</strong></p> <p>&ldquo;A world class plant has been built within the six years of our participation in the project. This is a pure &lsquo;greenfield&rsquo; project. The implementation of nanotechnologies, which constitute the core of the company&rsquo;s products, has allowed the company to become a market leader,&rdquo; said<strong> Dmitry Lisenkov,</strong> <strong>Managing Director, RUSNANO Management Company</strong>.</p> Tue, 12 Jul 2016 12:00:00 +0300 Russian Technologies Will Aid Indonesia in Space Exploration -indonesia-in-space-exploration <p>On October 31 the 11th session of the Russian-Indonesian Joint Commission on Trade, Economic and Technical Cooperation took place where RUSNANO that invests in the production based on the state-of-the-art developments in the field of nanotechnologies and the Indonesian infrastructure company with state support PT Wijaya Infrastruktur Indonesia signed an agreement on the establishment of the International Aerospace Equity Fund (IASF). The agreement was signed in the presence of the Minister of Industry and Trade of the Russian Federation <strong>Denis Manturov</strong> and Coordinating Minister for Economic Affairs of the Republic of Indonesia <strong>Darmin Nasution</strong>. On the Russian side it was signed by Managing Director for the Investment Activity of RUSNANO Management Company <strong>Dmitry Pimkin</strong>, on the Indonesian side&mdash;by President, CEO of PT Wijaya Infrastruktur Indonesia <strong>Didi Suwondo</strong>.</p> <p>Indonesia became the first foreign participant of RUSNANO Aerospace Fund. The initial size of the joint investment will amount to $100 million, which will be invested over 5 years in the development of navigation systems and satellite communication systems, in the production of new materials and components for satellites, in the development and manufacture of aircrafts and other related sectors of economy. The investment period can be extended for two years, and the operation period of the new fund is 10 years with possibility of extension for another three years.</p> <p>Expansion of IASF participants list is planned in the future by means of accession of other countries in the Asia-Pacific region that are interested in the creation of their pace infrastructure for telecommunications and monitoring of Earth&rsquo;s surface. RUSNANO plans to raise the level of the fund up to $500 million.</p> <p>According to the Managing Director for Investment Activity of RUSNANO Management Company, <strong>Dmitry Pimkin</strong>, &ldquo;rapidly growing economies of the Asia-Pacific countries&mdash;such as Indonesia&mdash;attract RUSNANO&rsquo;s close attention to this region. This attention is mutual: latest Russian technologies and developments &nbsp;recurrently prove their competitiveness in the world market. Moreover, aerospace expertise of Russia and Russian companies is beyond any doubt. The newly created Aerospace Fund will be one of the tools for Russia to promote domestic high-tech production in the world market, and for the partner countries it provides an opportunity to implement national commercial space programs.&rdquo;</p> <p>One of the first investment projects of the Fund will be the creation of its own satellite constellation that would form the basis of a system of prompt detection of fires and gas explosions. In general, IASF portfolio will be formed by projects that will solve a variety of tasks&mdash;from development and production of control systems for spacecraft to production of geosynchronous satellite systems and all the necessary ground infrastructure for the development of telecommunication network of the whole country.</p> <p>Russia, being one of the world leaders in the aerospace industry, has extensive experience in the development of outer space. The country has both experience in creation of advanced aerospace infrastructure and the latest developments in this field. RUSNANO is one of the key development institutions financing the introduction of new technologies in the Russian production.</p> Tue, 1 Nov 2016 12:00:00 +0300 White Metallurgy Company ETERNO Has Launched Production of Import-substituting Products Unique to the Russian Market. The Ceremony Was Attended by the President of the Russian Federation Vladimir Putin <p>Today, Chelyabinsk factory ETERNO founded by JSC Chelyabinsk Pipe-Rolling Plant (ChelPipe) and RUSNANO held a ceremony to mark the launch of production of stamp-welded parts (split tees) with the use of nanotechnology. The President of the Russian Federation <strong>Vladimir Putin</strong>, the Minister of Industry and Trade of the Russian Federation <strong>Denis Manturov</strong>, the Chairman of the Board of RUSNANO <strong>Anatoly Chubais</strong>, the Plenipotentiary Representative of the President of the Russian Federation in the Ural Federal District <strong>Igor Kholmanskikh</strong>, the Governor of the Chelyabinsk Region <strong>Boris Dubrovsky</strong>, and ChelPipe Group shareholders <strong>Andrey Komarov</strong> and <strong>Alexander Fedorov</strong> officially launched the production of the new import-substituting products.</p> <p style="text-align: center;"><img alt="" src="" /></p> <p>ETERNO&rsquo;s split tees will allow for conducting repairs of the main pipelines under a working pressure of up to 9.8 MPa and then putting them into operation without stopping the flow of hydrocarbons. Thus far, it has been foreign manufacturers that have carried out the supply and tying-in of split tees without interrupting flow for Russian energy companies. ETERNO is planning to produce up to 150 units of new products on an annual basis as part of its strategic projects. This includes the second line of the Novy Urengoy&mdash;Surgut product pipeline, the Nord Stream 2 pipeline, as well as the projects that meet the repair and maintenance needs of Gazprom, Rosneft, and other oil and gas companies in the CIS. Launch of ETERNO&rsquo;s new product range is a step towards almost entirely achieving full import substitution in pipeline production.&nbsp;</p> <p>&ldquo;We are in the process of becoming not only independent in terms of imports, but nanotechnology allows us to produce more reliable and more stable world-class level products. In collaboration with our partners, we are creating White Metallurgy&mdash;an area that fundamentally changes the perception of the industry as conservative and dirty. We are confident that our investment of over 4.5 billion roubles is of strategic importance,&rdquo; said Chairman of the Board of MC RUSNANO <strong>Anatoly Chubais</strong>.</p> <p>&ldquo;The domestic market for split tees is rapidly growing, and we are prepared to offer our customers a number of obvious competitive advantages: efficient execution of orders, an individual approach, and high quality products made with modern materials, technologies and equipment. The launch of split tee production sees ChelPipe Group taking its latest important step in developing integrated supply, guaranteeing that the consumer enjoys uniform high quality standards for each and every item on the product range: pipes, couplings and other pipeline components,&rdquo; said ChelPipe Group shareholder <strong>Andrey Komarov</strong>.</p> <p>The ceremony was also attended by graduates of the corporate educational program led by the ChelPipe Group&mdash;the Future of White Metallurgy. The young mechatronics specialists created a program that allowed for launching the machines and assembly units involved in the technical process of producing split tees automatically especially for the ceremony.</p> <p style="text-align: center;"><img alt="" src="" /></p> <p>After the official ceremony marking the launch of production, Vladimir Putin visited the exhibition of RUSNANO&rsquo;s nanotechnology projects in new industrial sectors, which was hosted at ETERNO&rsquo;s premises.</p> <p>During the visit, the President also held an informal meeting with the staff and long-standing employees of the ChelPipe Group&rsquo;s enterprises.</p> Thu, 8 Dec 2016 12:00:00 +0300 RUSNANO Delegation Headed by Anatoly Chubais, Will Take Part in the International Caspian Technology Forum <h5>RUSNANO Group takes part in the International Caspian Technology Forum held in Astrakhan on April 7-8.</h5> <p>Chairman of the Executive Board of RUSNANO Management Company LLC <strong>Anatoly Chubais</strong> will make a presentation at the plenary session on global technology trends that can seriously affect the performance properties of basic materials, energy generation and distribution as well as oil and gas production. The program of the working trip of the head of RUSNANO also includes meeting with the Governor of the Astrakhan Region <strong>A.A. Zhilkin</strong>, visiting of a number of industrial enterprises, which came up with an initiative on cooperation in the introduction of products of RUSNANO portfolio companies.</p> <div class="img"><img alt="Plenary session of the International Caspian Technology Forum" src="/upload/images/news/2016-04-07_Caspian_Forum_01_700.jpg" /> <p>Plenary Session of the International Caspian Technology Forum.<br />Chairman of the Executive Board of RUSNANO Management Company LLC Anatoly Chubais (L)<br />and the Governor of the Astrakhan Region Alexander Zhilkin</p> </div> <p>Everyone will be able to get acquainted with the products of portfolio companies at the RUSNANO stand in the exhibition of Caspian Technology Forum. Russia&rsquo;s largest producer of solar panels <a href="/portfolio/companies/hevel">Hevel</a> will show visitors the development of their own research center&mdash;photovoltaic cells with efficiency of solar flux conversion of more than 20%. At low cost of production, they combine the advantages of thin-film and silicon technology, are not subject to light-induced degradation and can be operated for more than 20 years.</p> <p>Perm manufacturer of oil-production equipment <a href="/portfolio/companies/novomet">Novomet</a> will introduce energy-efficient electric-centrifugal submersible pumps. Nanoscale coating of tungsten carbide, titanium and aluminum oxide, chromium and molybdenum is used in the manufacture of slide bearings and pump stages&mdash;it gives them high corrosion and hydroabrasion resistance, as well as reduces energy consumption by 20-30%.</p> <p>Novosibirsk project of RUSNANO&mdash;<a href="/portfolio/companies/ocsial">OCSiAl</a> will demonstrate not only their products&mdash;single-walled carbon nanotubes, but the actual methods for their use: long-lasting lithium-ion batteries, durable carbon and aluminum composites, electrically conductive rubber, concrete, cement and some other materials modified with nanotubes. In spite of high quality, the cost of carbon nanotubes by OCSiAl is 50 times lower than the cost of their equivalents, which opens up the possibility of their mass application in industry.</p> <div class="img"><img alt="The visit of RUSNANO’s stand in the exhibition zone of the International Caspian Technology Forum" src="/upload/images/news/2016-04-07_Caspian_Forum_02_700.jpg" /> <p>The visit of RUSNANO&rsquo;s stand in the exhibition zone of the International Caspian Technology Forum</p> </div> <p>In total, the Group stand represents products of 14 RUSNANO portfolio companies and startups of Fund for Infrastructure and Educational Programs network: foam glass gravel by ICM Glass Kaluga, machine vision systems based on the microprocessors for semantic processing of video streams VIP-1 by <a href="/portfolio/companies/elvees">Elvees NeoTek</a>, composite basalt-plastic fitting by <a href="/portfolio/companies/galen">Galen</a>, large diameter pipe fragment ChelPipe with corrosion-resisting coating <a href="/portfolio/companies/metaclay">Metaclay</a> and many others.</p> Thu, 7 Apr 2016 12:00:00 +0300 Nominations Submission for RUSNANOPRIZE 2016 Is Opened <p>In 2016 Rusnanoprize shall be awarded for research conducted in the fields of <strong>Medicine, Pharmacology and Biotechnology</strong>, as decided by the Board of the Fund for Infrastructure and Educational Programs and due to the Regulation of the Prize nomination field choosing procedures. &nbsp;</p> <p>&ldquo;Biotechnology, pharmacology, pharmaceutical and medicine are opening vast opportunities for nanotechnologies application, including drug delivery, targeted release systems, nano-biosensors and biomarkers, regenerative medicine, and many other areas&rdquo;, <strong>Sergey Kalyuzhny</strong>, Adviser to Chief Executive Officer&mdash;Chief Scientist of RUSNANO Group has noticed.&nbsp;</p> <p>RUSNANOPRIZE is an annual Prize awarded in one of the following fields:</p> <ul> <li>Optics and Nanoelectronics</li> <li>Nanomaterials and Surface Modification</li> <li>Medicine, Pharmacology and Biotechnologies</li> <li>Energy Efficiency and Green Technologies.&nbsp;</li></ul> <p><strong>Sergey Lukyanov</strong>, Doctor of Biological Sciences, Academician of the RAS (Russian Academy of Sciences), the Head of two subdivisions at the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (IBC) has become the first RUSNANOPRIZE laureate awarded in 2012 for achievements in Medicine, Pharmacology and Biotechnologies. He has been awarded for developing technologies and enabling production of the unique fluorescent proteins, together with Clontech labs awarded for commercialization of Dr. Lukyanov&rsquo;s work and marketing of a product line that has found demand from science and educational institutions and also from pharmaceutical and biotechnology companies.</p> <p>The Prize is awarded annually to researchers, scientists and developers (up to three people) being the authors of scientific-technological discovery or discoveries in the field of nanotechnologies, and to the company being the first to apply the discovery (discoveries) to mass production with the annual production output of at least $10 million and reached business success through the application of the discovery (discoveries). Financial rewards, prize symbols and honorary diploma of the Prize are awarded to inventors, scientists and developers, the authors of the R&amp;D projects or technologies implemented into production. The company that has achieved some significant commercial success due to the implementation of these technologies is awarded with an honorary diploma and a glass ball, which is a RUSNANOPRIZE symbol.</p> <p>Both Russian and foreign organizations as well as personalities, save for Prize Awarding Committee members, can nominate a researcher (researchers) for the Prize, self-nomination is also possible.</p> <p>Applications are accepted and registered by the Prize Directorate at rusnanoprize(at) in strict compliance with the nomination form.</p> <h5>For more details and application form, please visit <a href="" target="_blank"></a></h5> Thu, 28 Apr 2016 12:00:00 +0300 First Solar Diesel Electric Power Plant in the Trans-Baikal Territory Is Launched <p>On January 26, 2017, PJSC &ldquo;Rosseti&rdquo; in cooperation with Hevel Group of companies launched the first autonomous hybrid electric plant (AHEP) in the village of Menza, Trans-Baikal Territory, Russia, to provide uninterruptible power supply to three hard-to-reach villages.</p> <p>AHEP consists of solar modules of 120kW in total, two diesel generators of 200kW each, and a power storage device of 300kWh capacity.</p> <p>Use of solar modules and a modern intelligent control system of the electric plant will allow decreasing the consumption of diesel fuel from 250,000 to 86,000 litres per year. AHEP will decrease the atmospheric emissions of carbon dioxide by 500 tons within a year.</p> <p>The implementation of the project within the frameworks of public-private partnership has allowed to avoid the growth of the tariff burden on end consumers of the electric power, and guarantees the reduction of expenses from the regional budget due to the reduction of subsidies to compensate for the costs of the diesel fuel delivery. The project provider from the part of PJSC &ldquo;Rosseti&rdquo; was its subsidiary PJSC &ldquo;IDGC of Siberia&rdquo;.</p> <p><strong>Natalya Zhdanova</strong>, Head of the region, emphasized that the launch of the first solar diesel electric power plant in the Trans-Baikal Territory is an example of successful private-public partnership.</p> <p>&ldquo;Without any exaggeration, we are participants and witnesses of a significant event both for our region and our country in general. It is the first solar energy power plant in the Trans-Baikal Territory. At the same time, it is a good example of successful private-public partnership, an example of the fact that the authorities and businesses can jointly solve specific real-world problems.</p> <p>We have a lot of sun in the Trans-Baikal Territory. In addition, we have a lot of remote and hard-to-reach areas. Today, 23 residential localities of our region need stable and quality energy supply. Our task is to fully solve the problem of energy supply to these localities in the next three years. It is already planned to build two additional solar electric power plants in the region in 2017 in order to improve the quality of life of residents of the remote areas and provide their economic development.&rdquo;</p> <p>As <strong>Roman Berdnikov</strong>, First Deputy General Director, PJSC &ldquo;Rosseti&rdquo;, said: &ldquo;Rosseti is fulfilling a complex programme to modernize the network service complex in the Trans-Baikal Territory. I&rsquo;m sure that our experience of collaboration with the Trans-Baikal Territory will become a positive example for other Russian regions that are now looking for the solutions of the top-priority government task - to improve the reliability and quality of the power supply in the remote and isolated territories.&rdquo;</p> <p><strong>Igor Shakhray</strong>, General Director of Hevel Group of companies, noted: &ldquo;I&rsquo;m glad that we managed to jointly find such formula for the project fulfilment that helps improve the quality of life of residents in the remote and isolated areas and make this project cost-effective with no increase of expenses from the budget. The first return on investment will be completed within the frameworks of the energy-service contract and will be tied to reduction of expenditures for diesel fuel; therefore, we are, as investors, directly interested in the electric power plant efficiency increase.&rdquo;</p> <p>The autonomous hybrid electric power plant in the village of Menza is also a pilot project being a part of implementation of the National energy-sector project Development of Local and Integrated in the UES Sources of Energy Supply based on Photoelectric Heterostructure New Generation Modules.</p> <p>The programme of construction of over 100 autonomous hybrid electric power plants (AHEP) until 2021 was developed within the National project.</p> <p>The ceremonial launch of the first power plant was attended by: Aleksey Teksler, First Deputy Minister of Energy of the Russian Federation; Natalya Zhdanova, Governor of the Trans-Baikal Territory; Igor Shakhray, General Director, Hevel Group of companies; Viktor Pazdnikov, Minister of Territorial Development of the Trans-Baikal Territory; and Vitaly Ivanov, Acting General Director, PJSC &ldquo;IDGC of Siberia&rdquo;.</p> Thu, 26 Jan 2017 12:00:00 +0300 Roll Membrane Elements of RUSNANO’s Portfolio Company RM Nanotech Successfully Tested in Syria <p>Roll membrane elements produced by RUSNANO&rsquo;s portfolio company RM&nbsp;Nanotech have been successfully tested in Syria. Products of the leading European manufacturer of nanostructured membranes have been tested by engineering company Aquadamas whose integrator proved the high quality of the filters.</p> <p>The customer marked the high test results of RM&nbsp;Nanotech&rsquo;s products which demonstrate good quality at a competitive price (compared to their foreign counterparts). Representatives of RM&nbsp;Nanotech in cooperation with Syrian experts are preparing a major contract for the supply of filter elements to the Syrian government facilities.</p> <p>The reverse osmosis membrane elements of&nbsp;RM&nbsp;Nanotech fully comply with sanitary and epidemiological requirements and can be used to purify water of varying salinity. The new plant of RM&nbsp;Nanotech in Vladimir has significantly reduced the dependency of Russia on membrane materials import for water treatment and filtration systems.</p> Thu, 25 Feb 2016 12:00:00 +0300 RUSNANO's Portfolio Company Profotech and Maxwell Technologies SA (Maxwell) Have Signed an Agreement on Cooperation in the Field of Manufacturing and Marketing of Combined Optoelectronic Current and Voltage Transformers <p>France held the international exhibition CIGRE 2016, where RUSNANO&rsquo;s portfolio company Profotech and Maxwell Technologies SA (Switzerland) signed the Heads of Agreements on cooperation in the field of manufacturing and marketing of combined optoelectronic current and voltage transformers.</p> <p>The agreement sets out the principles of co-production, international certification and implementation of projects with the use of combined optoelectronic current and voltage transformers in Russia and internationally. This product, created by joint efforts of engineers and scientists of both companies, is a key element of building intelligent networks and digital substations and serves as a single source of data for all secondary smart devices.</p> Thu, 25 Aug 2016 12:00:00 +0300 Agreement Achieved to Commence the Work on the Set Up of the Russian-Indian High Technology Private Equity Fund <p>Within the official visit of the Prime Minister of India <strong>Narendra Modi</strong> to Russia, <strong>Anatoly Chubais</strong>, Chairman of the Executive Board of RUSNANO, and <strong>Shaktikanta Das</strong>, Finance Secretary of India, have agreed to commence the work on the set up Russian-Indian high technology private equity fund.</p> <p>It is envisaged that RUSNANO and the National Investment and Infrastructure Fund (NIIF) will invest $2 billion in equal shares and will establish a joint management company.</p> <p>The key areas of work of the private equity fund will be the implementation of the hi-tech projects at growth stage, including dual-use technologies and defense industry products. Technology transfer will be carried out with regard to the interests of both countries in creating the production facilities and service infrastructure on their territories.</p> <p>&ldquo;Russia and India have enjoyed a long history of mutually beneficial cooperation in various fields. The creation of the joint private equity fund is a new stage of development of our relations in harsh global market conditions. The Fund aims to strengthen the competitive position of Russian companies and promote the export of Russian high technologies into the promising Indian market&rdquo;, Anatoly Chubais emphasized. &ldquo;We have agreed that we would be ready to increase, if necessary, the size of the Fund which is to ensure greater efficiency of the processes of funding of joint innovative projects and contribute to the creation of high-skilled jobs in both countries&rdquo;.</p> Thu, 24 Dec 2015 12:00:00 +0300 RUSNANO’s Portfolio Company Profotech and Maxwell Technologies SA (Maxwell) Gave an International Presentation of their New Joint Product: Combined Optic-Electronic Current and Voltage Transformers <p>Profotech and Maxwell Technologies SA (Maxwell) gave a &lsquo;live&rsquo; presentation of their new joint product&mdash;combined optic-electronic current and voltage transformers (123 kV) at the 16th International Exhibition and Conference on Electric Power Equipment and Technology, EP China/Electrical China 2016, held in Beijing. Representatives of design, electric power, generation and engineering companies from China, India and Europe were invited to attend and discuss the product and solutions based on it.</p> <p style="text-align: center;"><iframe allowfullscreen="" frameborder="0" height="394" src="" width="700"></iframe></p> <p>Combined optic-electronic current and voltage transformers are a unique technology with no equivalent worldwide. They combine all the advantages of two electronic transformers in one. Their reduced size and weight compared to conventional electromagnetic transformers means that combined transformers can be installed even &nbsp;in small substations where there is limited space.</p> <p>This product is key in building smart networks, digital substations and serves as a single data source for all secondary smart devices.</p> <p>The product is the result of joint development work undertaken by engineers and scientists from both Profotech and Maxwell. Currently, the companies produce transformers able to handle 123 kV, but are planning to release higher voltage versions in the future.</p> <p>Maxwell will promote the new product on the international market.</p> <p>&ldquo;There is no doubt that our companies&rsquo; product will make a splash on the market of intellectual devices for smart grid networks in the near future. We can see great commercial potential for our new product. It is now even smaller, smarter, and, judging by the interest shown by Chinese and Indian energy companies at the exhibition, will undoubtedly be in demand in the near future! Profotech has already begun to expand its manufacturing output in light of the growing demand for its product,&rdquo; said <strong>Oleg Rudakov</strong>, General Director of Profotech.</p> Thu, 17 Nov 2016 12:00:00 +0300 RUSNANO and China Aerospace Science and Industry Corporation Signed a Strategic Cooperation Agreement <p>As a part of business trip to China on December, 17 RUSNANO and China Aerospace Science and Industry Corporation (CASIC) signed a strategic cooperation agreement in order to support development, production, export / import of high-technology industrial products, and expansion of bilateral investment cooperation. The document was signed by <strong>Boris Podolsky</strong>, Deputy Chairman of the Executive Board of RUSNANO, and <strong>Cao Jianguo</strong>, General Director of CASIC.</p> <p>RUSNANO and CASIC took a decision to integrate their opportunities for the purposes of high-technological projects implementation, as well as technical, commercial, and investment cooperation. Within the agreement contracts may be entered into both between RUSNANO and CASIC, and their subordinate undertakings, organizations, and portfolio companies.</p> <p><strong>The following key focus areas are determined:</strong></p> <ul> <li>Nanostructured ceramics</li> <li>Composite materials</li> <li>Plasma surface modification.</li> </ul> <p>A possibility of establishing RUSNANO and CASIC investment fund is stipulated by the agreement in order to implement joint projects. After internal corporate procedures a further work plan, parameters, and legal structure of the fund will be determined.</p> <p>The Parties also agreed upon application of strategic agreements with regard to the largest national companies and corporations, regions and provinces, as well as with other partners in order to develop joint business. Public and private investors, as well as institutes of development may be involved in cooperation. &nbsp;</p> <p>The agreement is also aimed at expansion of relations with large national corporations, industrial groups, and institutes of development.</p> Thu, 17 Dec 2015 12:00:00 +0300 Hevel Group to Increase Solar Generation in the Altai Republic up to 95 MW <p>Hevel Group (a joint venture between Renova Group and JSC RUSNANO) is to increase the amount of solar generation projects in the Republic of Altai. The corresponding arrangement was fixed in the agreement between the Government of the Republic of Altai and Hevel, which was signed at the St. Petersburg International Economic Forum.</p> <p>Let us recall that Hevel put two solar power plants each with a capacity of 5 MW <a href="/press-centre/news/20151222-the-second-stage-of-the-Kosh-Agach-solar-power-plant-brought-on-line-in-the-Republic-of-Altai">into operation in the Kosh-Agachsky district</a> of the Altai Republic in 2014 and 2015. These stations already supply electricity to the grid. At present, the construction of a third solar power plant in the region with a capacity of 5 MW, the Ust-Kan SPP, is being finalized.</p> <p>The signed agreement provides for the construction of five solar power facilities with a total installed capacity of 80 MW in Ongudaisky, Maiminsky and Ust-Koksinsky districts of the Altai Republic by 2020. The total volume of investment in the project amounts to over 12 billion roubles.</p> Thu, 16 Jun 2016 12:00:00 +0300 Anatoly Chubais Took Part in Panel Session The Big Challenges in Promoting Scientific Development at SPIEF 2016 <p>Chairman of the Executive Board of RUSNANO Management Company <strong>Anatoly Chubais</strong> spoke at the panel session The Big Challenges in Promoting Scientific Development that took place as part of the business program of the annual St. Petersburg International Economic Forum (SPIEF).</p> <p><iframe class="imgur-album" frameborder="0" height="560" src=";text=1a1a1a&amp;link=4e76c9" width="700"></iframe></p> <p>During his speech, Anatoly Chubais described the various stages of venture project financing and shared his experience related to the difficulties in relations between the investor and the financed company. He also noted the importance of the development of the innovative economy in Russia.</p> <p>Chairman of the Executive Board of MC RUSNANO <strong>Anatoly Chubais</strong>: &ldquo;Due to the fact that we built up the market economy itself from scratch, it has been vital to create an innovative economy in Russia as well. Yet it cannot be built on Soviet principles, if the whole economy in essence is a market economy. In this sense, we are lagging behind a little, but since 2005-2006, we have started to create this very innovative economy, without which there would be no demand for science. Much has been done and, despite continuous criticism, we can see the results of these efforts. However, the most important element is still lacking&mdash;the real interest of private business in the development of an innovative economy. We have already covered half the ground, and if we manage to cover the rest, we will have a real, well-founded, external demand for science.&rdquo;</p> <p>The panelists were: President of the Russian Academy of Sciences <strong>Vladimir Fortov</strong>, President of Skoltech <strong>Alexander Kuleshov</strong>, Chairman of the Scientific publishing house <strong>Elsevier B.V. Yonsuk Chi</strong>, Chairman of the Scientific Coordination Council of FASO Russia <strong>Yuri Balega</strong>, Professor of the University of Wisconsin-Madison (USA) <strong>Steven Durlauf</strong>, Vice President and General Manager in Central and Eastern Europe, IBM Corporation <strong>Michel Charouk</strong>, President of the Kurchatov Institute <strong>Mikhail Kovalchuk</strong>. The moderator of the session was Aide to the President of the Russian Federation <strong>Andrei Fursenko</strong>.</p> Thu, 16 Jun 2016 12:00:00 +0300 Telefonica Selects Quantenna Wi-Fi Client Solutions for Their Future Line of Wireless Set-Top Boxes <h5>Telefonica Will Integrate Quantenna&rsquo;s Wi-Fi Solutions for Their New Range of Wireless IP, Cable and Satellite Set-Top Boxes to Be Deployed Worldwide</h5> <p>Quantenna Communications, Inc., a leader in ultra-high performance Wi-Fi, announced today that&nbsp;Telefonica&nbsp;selected Quantenna&rsquo;s new QSR2000C product line to power all of Telefonica&rsquo;s new generations of wireless set-top boxes.</p> <p>Telefonica&rsquo;s new range of 4K ultra HD and HD wireless set-top boxes addresses all video service requirements and deployment topologies required by the various countries Telefonica operates in around the world: DTH, CATV, IPTV. Depending on the video service and countries, wireless set-top boxes will be powered by Quantenna&rsquo;s 4x4, 2x4 or 2x2 solutions.</p> <p>&ldquo;Telefonica has been deploying Quantenna&rsquo;s previous Wi-Fi solutions in their residential gateways, video bridges and set-top boxes,&rdquo; said <strong>Lionel Bonnot</strong>, Senior Vice President of Marketing and Business Development at Quantenna. &ldquo;We are honored that Telefonica renewed their trust in our solutions for their future generation of market leading wireless set box-boxes. We are particularly excited about the wide scope of the engagement and the breadth of technologies and geographical coverage it involves.&rdquo;</p> <p>From Telefonica&rsquo;s point of view, choosing a Wi-Fi supplier has become a strategic decision for the evolution of TV services. Wi-Fi performance is a key enabler for Telefonica to simplify the customer premises installation and to provide the higher quality of experience expected by Telefonica customers.</p> Thu, 15 Sep 2016 12:00:00 +0300 RUSNANO Successfully Quitted DANAFLEX-NANO <p>RUSNANO has completed the deal for sale of its share to Danaflex Group. RUSNANO&rsquo;s investments allowed for launching the most advanced production of packaging materials in Russia using nanotechnologies.</p> <p>Construction of Danaflex-Nano&rsquo;s plant began in 2009. Currently, the Company is an absolute leader of the flexible packaging market in Russia.&nbsp;Following the results of 2016, Danaflex-Nano&rsquo;s revenue should amount to approximately 7 billion roubles.</p> <p>The Company&rsquo;s clients include the leading Russian and international manufacturers of food products: Unilever, Nestle, Fritolay, Mondel&eacute;z, Maheev, Efko, Makfa, Mirital, Akkond, and many others.</p> <p>The key advantage of Danaflex-Nano&rsquo;s products is the possibility of considerable decrease in the amount of preservatives and increase in the shelf life of food products and other products packed using such wrap. This is achieved due to considerable decrease of the package permeability for oxygen and other aggressive environmental factors.</p> <p>&ldquo;The Company&rsquo;s success is a fortunate combination of several factors. I will place special emphasis on the contribution of Tatarstan&rsquo;s administration and personally Mr Rustam Minnikhanov who has supported our project from its very start. I hope to continue our cooperation with him in other areas. Tatarstan remains a priority region for us both from the point of view of scientific potential and its industrial opportunities. The second component of success is the entrepreneurial talent of the Company&rsquo;s founder Ayrat Bashirov, who has not only believed in the prospects of new technologies, but accepted the responsibility and risk related to their implementation and bringing them to the market. We expect that after RUSNANO quits the Danaflex project, it will continue demonstrating high growth rates and its commitment to innovations,&rdquo; Chairman of the Board of Management Company RUSNANO <strong>Anatoly Chubais</strong> noted.</p> <p>&ldquo;We have made a dramatic breakthrough due RUSNANO&rsquo;s investments. Recalling the time when our partner entered the project, then we had only flexible packaging production business running.&nbsp;When the deal was completed, we have become a high-tech company on the market both in flexible packaging production and film materials in Russia. From 2012 to 2016, we were annually included in the National Rating of Russian quickly growing technology companies &lsquo;Tekhuspekh&rsquo; (&lsquo;TechUp&rsquo;), We sincerely thank the administration of Tatarstan and RUSNANO for their support rendered to our Company at all stages of the project. Now we are setting new ambitious targets for further drastic development and export of our products to the global markets,&rdquo; the president of the Company DANAFLEX <strong>Ayrat Bashirov</strong> believes.</p> Thu, 15 Dec 2016 12:00:00 +0300 Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention <p>Selecta Biosciences, Inc.&nbsp;(NASDAQ:SELB) today announced that patient dosing has commenced in a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SELA-070, a nicotine vaccine candidate in development for smoking cessation and relapse prevention. The project is being funded primarily by an&nbsp;$8 million&nbsp;grant (#U01DA037592) from the&nbsp;National Institute on Drug Abuse&nbsp;(NIDA), part of NIH.</p> <p>Selecta&rsquo;s Synthetic Vaccine Particles (SVP&trade;) technology is designed to be a versatile platform and is being utilized in a series of programs aimed at inducing either antigen-specific immune tolerance or immune stimulation. SELA-070, an immune stimulation product candidate, delivers nicotine conjugated to the surface of nanoparticles that encapsulate immune stimulating agents. This second-generation product candidate is intended to induce a strong and durable immune response by triggering the production of a high level of anti-nicotine antibodies that bind to the nicotine inhaled by smokers, thus preventing nicotine from crossing the blood-brain barrier and triggering an addictive response.&nbsp;</p> <p>&ldquo;Smoking continues to profoundly impact our society and remains as one of our greatest public health challenges,&rdquo; said&nbsp;<strong>Werner Cautreels</strong>, Ph.D., CEO and Chairman of&nbsp;Selecta. &ldquo;We are very proud and motivated to be teaming with NIDA on this trial to determine if SELA-070 might benefit the millions of smokers in the U.S. and worldwide who are seeking ways to overcome their addiction and improve their health.&rdquo;</p> <p>Approved by the&nbsp;Federal Agency for Medicines and Health Products&nbsp;in&nbsp;Belgium, the Phase 1 trial is a double-blind, placebo-controlled, dose escalation study that is expected to enroll 48 smokers in&nbsp;Belgium. Patients will receive three injections of SELA-070 or a placebo over a period of 12 weeks followed by 8 weeks of monitoring. In addition to safety, the study will evaluate the vaccine&rsquo;s potency through the measurement of concentrations of nicotine-specific antibodies.</p> Thu, 11 May 2017 12:00:00 +0300 RUSNANO’s Portfolio Company Russian Quartz Will Significantly Expand Its Presence on the Global High-purity Quartz Market <p>RUSNANO&rsquo;s portfolio company Russian Quartz has launched the second phase of its quartz deep enrichment plant. Russian Quartz currently produces more than 3 million tons of quartz concentrate per year. After the second phase is put into operation, the production volume will increase threefold, which will allow the company to occupy 15% of the world market, and in the long term&mdash;25%. Thus, Russian Quartz edge out the current market leaders, American companies Unimin and Quartz Corp., and will strengthen its position as a supplier on the global market of high-purity quartz concentrates.</p> <p>Russian Quartz is a project based at the Kyshtym Mining facility. RUSNANO joined the project in 2011 and invested 562 million roubles in it. In 2013, the Japanese financial and industrial holding company Sumitomo Corporation became a co-investor in Russian Quartz. This is the first project that RUSNANO has implemented in cooperation with a Japanese partner. RUSNANO currently owns 28.69% of the company, the same as Sumitomo Corporation. The remaining share belongs to the company management.</p> <p>The share of exports in the Russian Quartz&rsquo; revenue model amounts to 97%. The main foreign markets are China, Japan and the EU. Buyers include international giants such as SUMCO (Japan), Covalent (Japan), Osram (Germany), Philips (Netherlands), and JNC (China).</p> <p>Russian Quartz produces&nbsp;high-purity quartz concentrate, which is used in a number of high-tech industries. The uniqueness of the deposit, as well as the company&rsquo;s specialists&rsquo; know-how pertaining to the enrichment and cleaning of the raw material will allow for obtaining the end product of the highest purity. As a consequence, Kyshtym quartz is part of the international technological production chain of microelectronic chips and solar power plant modules.</p> <p style="text-align: center;"><img alt="" src="" style="width: 100%;" /></p> <p>At the opening ceremony, Chairman of the Board of MC RUSNANO <strong>Anatoly Chubais</strong> said: &ldquo;We are opening the second production line of ultrapure quartz at Russian Quartz plant located in Kyshtym. It is a joint project with our Japanese co-investor, the holding company Sumimoto. What does this mean for us and for the economy as a whole? Increased production and the chance to occupy a quarter of the global market. Moreover, we will put pressure on our serious competitors from the USA. We will strengthen our position in global supply chains in the production of electronics, and reinforce our partnership with global giants. Expanding production will bring 400 new jobs to the region.&rdquo;</p> <p>&ldquo;Our company Sumitomo Corporation (Central Eurasia) LLC is very much excited being involved in the development of Russian Quartz, promising export oriented manufacturer of Russia.&nbsp;Sumitomo Corporation Group, which we are representing in CIS region, is a large Japanese trading conglomerate. Being a Trading company we rather concentrated in exporting Japanese products to Russia in the past,&nbsp;but now our&nbsp;ultimate purpose is to be an established Russian Company and contribute a lot to this Country. In this regard, we wish Russian Quartz a great success having constant guidance and co-operation of our reliable and respected Partners, namely Kyshtym Mining KGOK&nbsp;JSC and RUSNANO,&rdquo; said <strong>Keiji Ikemura, </strong>President and CEO Sumitomo Corporation (Central Eurasia) LLC.</p> Sun, 4 Dec 2016 12:00:00 +0300 RUSNANO and the Ministry of Science and Technology of China Signed a Cooperation Agreement <p>The Agreement was signed in the course of the visit of the Russian President <strong>Vladimir Putin</strong> to China. The Chairman of the Board of RUSNANO <strong>Anatoly Chubais</strong> and the Minister for Science and Technology of the People&#39;s Republic of China <strong>Wan Gang</strong> endorsed the document.</p> <p style="text-align: center;"><img alt="RUSNANO and the Ministry of Science and Technology of China Signed a Cooperation Agreement" src="/upload/images/news/2016-06-25_China.jpg" /></p> <p>The parties have agreed to create a Russian-Chinese High Technology Direct Investment Fund. The Fund is to support the two-way transfer of technologies between China and Russia and import of technologies from third countries for further establishment of industrial enterprises, branches, representative offices and R&amp;D centers in Russia and China.</p> <p>The Agreement also stipulates the establishment of a joint R&amp;D Center or a Nanotech Incubator in Russia and China.</p> <p>&quot;Despite an unfortunate recent downswing in the trade and investment cooperation between our countries, the Russian-Chinese relationship can be unequivocally described as full-fledged and amicable. RUSNANO has been actively and effectively collaborating with Chinese partners, and today&#39;s entering into the Agreement with the Ministry of Science and Technology of China should give our cooperation a new impetus,&quot; stressed Anatoly Chubais.</p> Sat, 25 Jun 2016 12:00:00 +0300 JSFC Sistema and RUSNANO Create a Fund of Direct Investments <p>PJSC JSFC Sistema (hereinafter referred to as the JSFC Sistema) (LSE: SSA, MOEX: AFKS), a public Russian diversified holding company, and RUSNANO announce the start of a joint direct investments fund oriented towards investments in high-technological companies and projects.</p> <p>The total amount of the fund is up to $100 mln. JSFC Sistema and RUSNANO participate in the fund in equal proportion. Resources will be directed to the Fund in proportion to financing of specific transactions.</p> <p>The Fund has been created for 7 years with the possibility of prolongation for three more years. The average amount of one investment is ;5-20 mln. In the future third-party investors will be able to participate in the Fund.</p> <p>The Fund will be involved in investing in high-technological projects at the initial stage as well as in growing and already developed companies in Russia, CIS countries, Europe and Israel. The fund is mainly focused on microelectronics, energy efficiency, robotic technology, information and communication technologies and other fields.&nbsp;</p> <p>&ldquo;RUSNANO has entered into a new stage of the investment cycle, which consists in creation of joint funds to which not only our resources but also resources of professional private investors will be attracted. Thus, we will be more active in promoting the private equity market of high technologies and industry,&rdquo; said the Deputy Chairman of the Board&mdash;Executive Director of Management Company RUSNANO <strong>Boris Podolskiy.</strong></p> Mon, 5 Sep 2016 12:00:00 +0300 Chemist: We Are on the Brink of the Age of Genetic Medicine RIA Novosti, Oct 30, 2016 <h5>American chemist Chad Mirkin, the laureate of the RUSNANOPRIZE 2016, explained RIA Novosti how his nanoparticles will open the age of genetic medicine, may help women get rid of wrinkles and bring us closer to defeating cancer, as well as assured us that the nanomachine-related Apocalypse is a thing of science fiction or deep future.</h5> <p>Chad Mirkin is one of the most renowned American chemists, he&rsquo;s the foremost expert on spherical DNA and RNA molecules and their combination with metal nanoparticles and other inorganic materials. Apart from &lsquo;organic&rsquo; DNA nanoparticles, Mirkin and his team at Northwestern University near Chicago have developed ways of making and printing nanostructures on surfaces for applications in electronics and optics.</p> <p>Mirkin was considered to be one of the top contenders for the Nobel Prize in chemistry in 2013 by the Thomson Reuters bureau and many other experts and has been a contender ever since. He was also nominated in the past for the RUSNANOPRIZE, which is awarded by the Russian nanotech company RUSNANO for development of nanotechnologies and their practical applications since 2009.</p> <div class="img"><img alt="Chad Mirkin" src="" style="height: 397px; width: 700px;" /> <p>Photo: RIA Novosti</p></div> <h4>&mdash; Chad, the geneticists often face a huge backlash by the society and the politicians when they work on DNA editing technologies, such as CRISPR, as well as GMO products. Somehow, nanoparticle research avoided all that; can you explain why did that happen?</h4> <p>&mdash; In this case, I think, there&rsquo;s a fundamental difference between nanoparticle research and GMO research.In the case of nanomaterials, we deal with a subset of chemical research, in which we try to find new and useful properties of different materials that are purely artificial and a consequence of miniaturization. Every bulk material when miniaturized is different. Gold is not gold in color when made on the nanoscale&mdash;it is red. This is why the field is so exciting. Everything becomes new and different when miniaturized, and those differences can be used to develop many new technologies. On the other hand, DNA editing and GMO production is a technique, performed using well-defined biochemical processes and they involve permanently manipulating living organisms. This creates ethical considerations and has drawn the attention of regulators and people concerned about long-term consequences to life itself.</p> <p>Of course, there are people who are afraid of nanotechnologies, but it&rsquo;s really hard and unfair for them to paint all nanotechnologies with the same brush and claim that all of them are bad or good by definition. If you think of it, many things that were created in science in recent years can be called &lsquo;nanotech&rsquo; in one way or another. After all, many molecules, the product of chemistry, are smaller than the building blocks and structures we refer to as nanomaterials.</p> <p>For example, the structures we are working with should not be classified as nanoparticles&mdash;it is too general of a term. They are, as we call them, spherical nucleic acids, a completely new type of nano- and chemical structure, which we can be created by coating specific metallic structures with short strands of DNA or RNA, which allows us to generate particles of pre-determined size, shape and function. There&rsquo;s nothing like them in nature, yet they interact with living matter and cells in unusual and useful ways. They are a triumph of the convergence of chemistry, biology and nanoscience.</p> <h4>&mdash; You were once named as a likely candidate to receive a Nobel prize for your research in the are of DNA nanotechnology. This year it was awarded to a trio of scientists who worked on nanomachines. What do you think about it?</h4> <p>&mdash; Well, this time it was awarded for discoveries that have nothing to do with our research. Feringa, Sauvage and Fraser Stoddart&mdash;my colleague at Northwerstern, by the way&mdash;created the building blocks from which crude molecular machines can be created. These nanomachines replicate in a simplistic manner what macroscale machines or machine parts like rotors and switches can do.</p> <p>So, yes, you can say that this year&rsquo;s Nobel Prize went to nanotech research, but you have to understand that nanotechnology is very vast, and it covers so many things, spanning energy research, electronics, optics and medicine. In this particular case, our research is in a completely different category from what this year&rsquo;s Nobel Prize winners were doing.</p> <p>If we talk about me personally, I have no answer for you&mdash;it&rsquo;s not up to me to decide who and when they should get the Nobel Prize, let&rsquo;s leave that for the Nobel Prize committee.</p> <h4>&mdash; At the Nobel Prize press-conference, Ben Feringa was asked if the nanomachines pose any threat to humanity now or in the future. He told the reporters that he thinks they won&rsquo;t ever be a credible threat for us. Do you think that is true?</h4> <p>&mdash; Again, if we look closely at this year&rsquo;s Nobel Prize, we&rsquo;ll see that it was awarded for a very fundamental discovery. I think that we are now at a very early phase of chemical nanotechnology, and far away from the types of machines that science fiction writers invoke as entities that could cause the extinction of life on Earth in the infamous &lsquo;grey goo&rsquo; scenario.</p> <p>The idea that nanomachines are being built that could rebel is a product of science fiction that has little to do with the actual science. I think this idea will remain in that field of thought for a long time to come. The nanomachines that we have now are really crude demonstrations that can&rsquo;t do anything functional on their own.</p> <p>Generally speaking, they are not the nano-Terminator devices that some propose will cause problems for humanity. In my opinion, decades, if not centuries, will pass before we have to discuss this problem on a serious level, if at all.</p> <h4>&mdash; In which areas of nanotechnologies do you expect the most progress to happen in the nearest future?</h4> <p>&mdash; First, our spherical nucleic acids are being widely used in medicine and the life science industry. Some of them are already used for medical diagnostics in clinics and hospitals&mdash;for example, spherical nucleic acids with gold nanoparticle cores are used as labels for the very precise and fast search of specific DNA sequences, proteins and other types of molecules associated with disease in biological samples.</p> <p>These particles can be used to detect viruses, bacteria or cancer cells in samples of saliva, blood or urine, as well as determining if a patient is genetically predisposed to a specific type of disease. This is all already implemented in practice.</p> <p>Much more awaits us in the future. We are now creating a new kind of spherical nucleic acid that can be filled with other types of molecules, and these particles can infiltrate into cells and tissues like no other DNA or RNA molecules can.</p> <p>For example, we can add those nanoparticles to a kind of cream that you can rub into your skin and that cream can be used to address more than 200 types of genetic diseases that afflict skin cells and tissues. In the same way, we can create medicines that alleviate irritable bowel syndrome in the colon, macular degeneration and other diseases of the eye, or problems with the lungs or bladder. In other words, we are now on the brink of the age of genetic medicine.</p> <p>It&rsquo;s really important to understand that you need three things to make that dream come true. First, we need robust ways of creating and designing DNA and RNA molecules. We learned how to do that about 30 years ago. Second, we need to understand why this or that mutation in a specific gene causes a particular disease. We have this information from the Human Genome Project and related efforts.</p> <p>The third thing&mdash;the ability to get DNA to the place in the body where you need it&mdash;was eluding us until this moment. As it happened, spherical nucleic acids are perfect for that&mdash;now we can target any organ or any tissue in the body, and not only the liver like all other methods of gene regulation therapies. We don&rsquo;t even have to make our particles tissue specific because we can directly and topically apply them to the afflicted organ.</p> <h4>&mdash; Some time ago you managed to turn DNA into crystals. Have you found any practical application for such crystals?</h4> <p>&mdash; If there was a Nobel Prize in this area, I&rsquo;d say that the methods for making such crystals would qualify. We got interested with spherical nucleic acids back in 1996 for reasons that had nothing to do with medicine or biology.</p> <p>We had introduced the concept that you can view nanoparticles as atoms and DNA as a programmable bond and developed the design rules to assemble them into a multitude of crystalline forms. We can mix and match different particles and build crystals with extraordinary complexity from the bottom up.</p> <p>We can control the placement of all these &lsquo;atoms&rsquo; with sub-nanometer precision using the power of DNA bonds. It turned out that it paved the way for an entire new field of materials science, and now we can build materials that we want by designing them to have the properties we desire instead of relying only on what nature offers.</p> <p>Today we have designed nanoparticles that have allowed us to create over 500 different types of crystals, six of which do not even exist in nature. Why is that interesting? Thanks to the diversity of the nanoparticles we have created, the number of such combinations is nearly infinite as well as the new properties that can be realized.</p> <p>Although the practical side of this aspect of spherical nucleic acid research is a decade off, we believe these crystals will be the route to new types of designer catalysts and optical materials and devices that control light in ways we&rsquo;ve never seen before.</p> <h4>&mdash; When you created spherical DNAs, you said that it can be possibly used for cosmetic purposes, i.e. wrinkles removal. Did any of the cosmetics companies contact you?</h4> <p>&mdash; Yes, many corporations approached us. The potential of the spherical nucleic acids is nearly limitless from the cosmetic standpoint&mdash;we can use them to make the skin more elastic, we can use them to remove dark spots in the skin by forcing cells to stop the production of the pigment molecules that make skin go dark, as well as to do many other things.</p> <p>However, there&rsquo;s a problem&mdash;it&rsquo;s not clear how such products will be regulated. They can be viewed as either cosmetics, pharmaceuticals or cosmeceuticals, and it&rsquo;s not clear how their safety will be tested.</p> <p>In addition to that, from a business standpoint and from a health standpoint, the development of cosmetic nanoparticles gives way to disease and cancer research, which is much more important for us and&nbsp; patients than wrinkles or other cosmetic problems.</p> <h4>&mdash; In the recent years scientists published hundreds, if not thousands of papers devoted to this or another &lsquo;material of the future&rsquo;, for example, plasmonics or DNA origami. In time, they sort of &lsquo;evaporated&rsquo; and we don&rsquo;t really hear about those &lsquo;wonder&rsquo; materials anymore. Why does it happen?</h4> <p>&mdash; In fact, I would not say that all such research evaporated&mdash;both plasmonics and origami research are still going strong, although it&rsquo;s probably safe to say that origami in the short term will remain purely a fundamental kind of science. But who knows what will happen 30 years from now?</p> <p>Just remember the story of lasers. When scientists first created lasers, someone said, as far as I remember: &ldquo;this is an interesting discovery that is looking for a use&rdquo;. Decades later, lasers are everywhere&mdash;you can see lasers when you check out your groceries in the supermarket, they are used for conducting surgery in hospitals, each computer and communication system has at least one of them.</p> <p>In other words, sometimes a fundamental kind of discovery takes not only months or years, but decades before it finds its practical and commercial use.</p> Mon, 31 Oct 2016 12:00:00 +0300 RUSNANO Withdraws with Profit from the Project with Mikron <p>RUSNANO proceeds to selling the share in its portfolio company PJSC Mikron (previously OJSC Research Institute for Molecular Electronics (RIME) and Mikron). AFC Sistema acts as the buyer in the deal. The withdrawal will be implemented before the end of 2017. Total income will amount to 8.1 billion rubles.</p> <p>RUSNANO entered the project in 2009 to create on the basis of Mikron a technological line for the production of integrated microcircuits with a topology of 90 nm, which was launched in February 2012. At the end of 2014 the Company released the first domestic dual-core microprocessor &ldquo;Elbrus-2CM&rdquo; developed by CJSC MCST and manufactured using 90-nanometer technology.</p> <p>Today, Mikron is the largest manufacturer of microelectronics in Russia, CIS and Eastern Europe, the only Russian semiconductor manufacturer working on topological norms of 180-90-65 nanometers. Mikron supplies its products to Russian and foreign customers, including communications providers, largest national transportation companies, banks and public authorities and institutions. The range of Mikron products include microprocessors for electronic identification documents, bank cards of NPCS &ldquo;Mir&rdquo; and SIM-cards, RFID-chips and tags for various applications, smart cards on their basis, discrete semiconductors, power management chips and aerospace electronics.</p> <p>&ldquo;I think the project with Mikron is a landmark not only for RUSNANO, but also for the Russian economy as a whole, because microelectronics is the basis for many innovative sectors. Internet of Things, self-driving vehicles, augmented and virtual reality, space, robotics&mdash;it is difficult to find a modern sector without an electronic microchip in its core. Moreover, the creation of its own microelectronic base is also the issue of stability and competitiveness of the country. I also want to note that in our project AFK Sistema has shown itself as a reliable and professional partner, and we look forward to further mutually beneficial cooperation,&rdquo; said<strong> Oleg Kiselev</strong>, Deputy Chairman of the Board of the Management Company RUSNANO.</p> Mon, 31 Oct 2016 12:00:00 +0300 RUSNANO Transfers Russian Representative Powers to Kurchatov Institute in XFEL Project <p>In accordance with the RF Government decree of May 18, RUSNANO transfers its shares in the international European X-ray free electron laser (XFEL) project to the National Research Centre Kurchatov Institute.</p> <p>The XFEL X-ray laser is a unique research project involving 11 countries. The facility will generate femtosecond flashes of high-energy radiation, which will allow scientists to investigate the structure of biological molecules and a variety of materials, and monitor ultrafast biological and chemical processes. The X-ray laser is composed of an electron accelerator and undulators (magnets) which will deflect the electrons from the rectilinear trajectories, thereby causing the emission of synchrotron radiation.</p> <p>The decision to create the facility was made in April 2009. The construction of the six-kilometre system of tunnels and underground experimental halls for the XFEL is already finished. Now, the experimental equipment is being installed on the site. It is expected that the first experiments at XFEL will begin in April 2017.</p> <p>In 2009, Russia became one of the 11 participating countries; it was represented by JSC &ldquo;RUSNANO&rdquo;, whose share in the capital of the European XFEL GmbH totalled 26.24 percent. By order of the Government of the Russian Federation, RUSNANO invested on behalf of Russia in the construction of the XFEL, and in turn, the Kurchatov Institute carried out the scientific management of the project. The collaboration between RUSNANO and the Kurchatov Institute not only facilitated the participation of Russian researchers in shaping of the XFEL research program, but also created orders for Russian companies for the equipment and materials needed for the construction of the facility.</p> <p>As the project moves from the construction stage to the actual solving of operational issues, the Russian government decided to transfer the powers in the project from RUSNANO to the National Research Centre Kurchatov Institute.</p> Mon, 30 May 2016 12:00:00 +0300 Russia and Iran Have Agreed to Cooperate in the Field of Nanoproduct Certification <p>Russian nanoindustry companies will interact with their Iranian counterparts in the field of safety assessment and certification of nanotechnology products.</p> <p>The corresponding agreement was signed on Wednesday in Tehran by the Director General of the ANO Nanocertifica Centre for Certification of Nanoindustry Production and Management Systems, <strong>Sergey Volkov</strong> and the Director of the International Collaboration and Nanostandardization Committee of the Iran Nanotechnology Initiative Council <strong>Ali Beitollahi</strong>.</p> <div class="img"><img alt="Russia and Iran Have Agreed to Cooperate in the Field of Nanoproduct Certification" src="/upload/images/news/2016-05-20_Iran-Nano-Forum.jpg" /> <p>The corresponding agreement was signed by the Director General of the ANO Nanocertifica Centre for Certification of Nanoindustry Production and Management Systems, Sergey Volkov (L) and the Director of the International Collaboration and Nanostandardization Committee of the Iran Nanotechnology Initiative Council Ali Beitollahi</p></div> <p>The document was signed within the framework of the International Forum on Nanotechnology Products Certificates and Labeling, which was attended by the representatives from South Korea, Taiwan, Thailand, Malaysia, and Kazakhstan including Russia and Iran.</p> <p>The agreement provides joint testing of products, improvement of the assessment methodology and ensuring safety in the nanotechnology industry, as well as the development of measuring and testing methods. The parties agreed to establish a working group, which will form a road map for conducting joint work in the sphere of standardization, certification and safety assessment of nanoindustry production.</p> <p>While signing the agreement, Mr. Volkov and Mr. Beitollahi confirmed their mutual interest in the harmonization of regulations in the nanoindustry, the creation of unified approaches to the assessment of nanosafety, as well as the development of procedures for the certification of nanotechnology production thus ensuring the mutual recognition of its results.</p> Mon, 23 May 2016 12:00:00 +0300 Quantenna Communications Launches Initial Public Offering <p>Quantenna Communications, Inc. (&ldquo;Quantenna&rdquo;), a provider of high-performance Wi-Fi solutions, today announced that it expects to launch the initial public offering (IPO) of its common stock on October 17, 2016. The offering is for 6.7 million shares at an initial price range of $14.00 to $16.00 per share. The Company also expects to grant the underwriters an option to purchase up to 1,005,000 additional shares.</p> <p>Quantenna has applied to list its common stock on the NASDAQ Global Select Market under the ticker symbol QTNA. Morgan Stanley, Barclays and Deutsche Bank Securities are acting as joint bookrunners for the transaction. Needham &amp; Company, William Blair, and Roth Capital Partners are acting as co-managers.</p> <p>The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from: Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at <a href=""></a>; or from Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005, by telephone: 1-800-503-4611, or by email at <a href=""></a>.</p> <p>A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p> Mon, 17 Oct 2016 12:00:00 +0300 Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) <p>Selecta Biosciences, Inc.&nbsp;(NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced new preclinical data regarding non-immunogenic gene therapies that were presented at the&nbsp;American Society of Gene &amp; Cell Therapy&nbsp;(ASGCT) 2017 Annual Meeting, which took place last week in&nbsp;Washington, D.C.</p> <p>&ldquo;Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,&rdquo; said&nbsp;<strong>Werner Cautreels</strong>, Ph.D., CEO and Chairman of&nbsp;Selecta. &ldquo;Together with various collaborators, we have again demonstrated the potential of Selecta&rsquo;s proprietary immune tolerance Synthetic Vaccine Particles (SVP&trade;) technology, which is designed to improve the clinical benefits and transform the development of gene therapy. We also were pleased with the presentation of preclinical proof-of-concept data for our proprietary product candidate in MMA, a life-threatening rare disease that can only be treated today by diet or organ transplantation.&rdquo;</p> <p>A team led by&nbsp;<strong>Charles Venditti</strong>, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the&nbsp;National Human Genome Research Institute&nbsp;at the&nbsp;National Institutes of Health, and&nbsp;<strong>Luk Vandenberghe</strong>, Ph.D., Director of the&nbsp;Grousbeck Gene Therapy Center&nbsp;at Mass. Eye and Ear and an Assistant Professor at&nbsp;Harvard Medical School, delivered a presentation entitled &ldquo;Anc80 Mediates Hepatic Correction of Methylmalonyl-CoA Mutase Deficiency in Murine Models of Methymalonic Acidemia.&rdquo; This presentation featured data from mouse models of MMA, a rare inborn error of metabolism most frequently caused by mutations in the enzyme methylmalonyl-CoA mutase (MUT). In this study, MUT-deficient mice were treated with Selecta&rsquo;s Anc80-synMUT product candidate to express the human MUT gene. The gene therapy induced a robust biochemical and clinical response as plasma methylmalonic acid levels dropped precipitously, substantial weight gain ensued and survival was sustained. Further, presented data indicate that the combination of SVP and Anc80 could effectively overcome the immunogenicity that has limited other gene therapy programs by enabling enrollment of patients with pre-existing antibodies to AAV and keeping patients eligible for repeat administration.</p> <p>A team led by&nbsp;<strong>Federico Mingozzi</strong>, Ph.D., Head of Immunology and Liver Gene Therapy at Genethon, delivered a presentation entitled &ldquo;Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via&nbsp;Repeated Co-Administration&nbsp;of Vector with Rapamycin Tolerogenic Nanoparticles.&rdquo; This presentation featured data from both mouse and non-human primate studies demonstrating how the co-administration of SVP-Rapamycin completely blocked anti-AAV immune responses in an antigen-specific manner and allowed for vector re-administration and gene therapy dose titration. The ability to dose titrate could provide for more effective development and administration of gene therapies.</p> Mon, 15 May 2017 12:00:00 +0300 RUSNANO’s Long-Term Development Program Approved <p>The Board of Directors of RUSNANO has approved the company&rsquo;s updated long-term development program up to 2020. The program is executed pursuant to the orders of the Government of the Russian Federation.</p> <p>The strategic vision of the company remains unchanged, RUSNANO is committed to becoming the Russian global investor in technology specializing in investment (directly and through nanotechnology investment funds) in competitive Russian and foreign companies implementing promising nanotechnologies. By 2020 RUSNANO is expected to become an internationally recognized leader in the hi-tech investment sector.</p> <p>The import substitution industrialization, a priority of national economic policy, made the basis of the new direction of the long-term development program. In particular, RUSNANO will participate in the production of essential import substitution products through its project companies in 2015&ndash;2020. In cooperation with the Fund for Infrastructure and Educational Programs (FIEP) RUSNANO is planning to implement approximately 10 pilot projects within the import substitution programs promoted by the Ministry of Industry and Trade and the Ministry of Energy of Russia.</p> <p>Among the most important tasks of RUSNANO is to actively attract private investors to the industry by creating investment nanotechnology funds with the participation of OJSC&nbsp;RUSNANO (co-)&nbsp;managed by Management Company RUSNANO. Along with the development of success stories, the ratio between RUSNANO&rsquo;s targeted investment amount and third party investments will be initially going down from 1:1 in 2015&ndash;2016 to 1:4 and more for the funds to be created by 2020.</p> <p>The Board of Directors of RUSNANO has also approved the company&rsquo;s key performance indicators for the period up to 2020 (with the intermediate indicators included) outlined in the long-term development program. <em>RUSNANO Portfolio Companies Production Turnover</em> is one of the key indicators to reach RUB&nbsp;600&nbsp;bln by 2020. 100&nbsp;facilities, engineering and research centers are expected to be launched with the participation of RUSNANO by then.</p> <p align="center">* * *</p> <p>The Board of Directors has approved the additional financing for&nbsp;Optic&nbsp;Fiber&nbsp;Systems, a portfolio company of RUSNANO. The funds allocated on a par with Gazprombank will help the facility to reach its design capacity at an early date. The company&rsquo;s goal is to capture 20% of the Russian fiber optic market.</p> <p align="center">* * *</p> <p>With regard to debt financing, the Board of Directors of RUSNANO has approved the addition to the agreement on the non-revolving credit line in the amount of RUB&nbsp;11&nbsp;bln with Promsvyazbank. This additional agreement specifies the drawdown and settlement schedules. The Board has also approved the state guarantee agreement constituting a related party transaction executed to secure the mentioned credit.</p> Mon, 14 Dec 2015 12:00:00 +0300 The Development by RUSNANO Portfolio Company OptoSense Will Allow to Significantly Reduce Coal Mine Accidents <h5>OptoSense proceeds to delivery of hydrocarbon sensor with the lowest ever power consumption.</h5> <p>OptoSense, RUSNANO portfolio company, has begun commercial delivery of the most advanced infra red hydrocarbon sensors MIPEX-04, that, among other things, will be used for provision of the miners&rsquo; personal safety. It is no secret that the miners still die as a result of methane explosions in coal mines. A revolutionary development by OptoSense will allow preventing the accidents much more effectively, thus saving lots of human lives.</p> <p>Power consumption of the innovative sensors is 1000 times less than that of the competing analogues, which means that the devices in use can operate for over 2 years on a single charge instead of several hours. Leading international players in the market of industrial safety such as Honeywell Analytics, which has already started to sell personal gas analysers based on the sensor, are among the buyers of MIPEX-04.</p> <p>New generation of sensors created by OptoSense consumes less than 100 microwatt of power which opens the door to multiple opportunities for development of the most advanced devices and solutions to detect and measure explosive gas concentrations, including the creation of the new market of portable clip gas analysers &ldquo;from scratch&rdquo;.</p> <p>The unique features of new sensors have become possible thanks to semi-conductive polycrystal nanoscale layers in the mass fabrication of the sensor key elements, namely light-emitting diode sources and photovoltaic detectors. It is the availability of MIPEX-04 that allowed achieving such outstanding parameters of time of operation of the final device without the need for maintenance during the service life for the first time in the international practice.</p> <p>OptoSense specializes in manufacturing of infrared optical sensors to determine explosive gas concentrations, primarily, hydrocarbons. Up to now, almost 100 international and Russian producers of gas analysers are the company&rsquo;s customers. Furthermore, almost 70% of the company&rsquo;s products are sold in the USA and Europe.</p> <p>Gas analysers based on OptoSense sensors are used to provide personal and industrial safety in oil and gas or petrochemical industry (extraction, transportation and processing of oil and gas), coal mining (in mines), power industry (gas-fired plants), telecommunications (maintenance of underground cable networks). The total scope of gas analyser market as estimated by Frost &amp; Sullivan is about $2 billion with potential increase to $3 billion by 2018.</p> Mon, 13 Feb 2017 12:00:00 +0300 Having Got Double Return of Investments, RUSNANO Exits the Magnesium Oxide and Hydroxide Production Project <p>RUSNANO sells its ownership interest in the NikoMag portfolio company, specializing in production of <nobr>nano-structured</nobr> magnesium hydroxide (a fireproofing additive, the substance inhibiting inflammation and fuming processes), <nobr>high-purity</nobr> magnesium oxide (used in production of transformer steel and general mechanical rubber goods) and magnesium chloride used in oil- and <nobr>gas-production,</nobr> production of construction materials and in ice control activities.</p> <p>The total project budget amounts to RUB 3.8&nbsp;bln, including the RUSNANO ownership interest of RUB 1.3&nbsp;bln. The purchaser of the RUSNANO ownership interest is the Group of Companies NIKOCHEM. Proceeds from this transaction are 200% greater than the investments made.</p> <p>RUSNANO entered the project in 2010. During this time, there was built, equipped, and developed to its project capacity a unique plant, having no equals in Russia, occupying the area of 4.5&nbsp;ha, and currently employing 262&nbsp;employees.</p> <p>The production capacity for magnesium hydroxide is 25&nbsp;thousand tons a year; for magnesium oxide, 30&nbsp;thousand tons a year. Before launching NikoMag, both products were wholly imported into Russia. In the nearest future, the company plans to occupy almost 100% of the Russian synthetic magnesium hydroxide market and 90% of the <nobr>high-purity</nobr> magnesium oxide market. NikoMag is included into the import substitution action plan for the chemical industry approved by the Ministry of Industry and Trade of the Russian Federation.</p> <p>NikoMag&rsquo;s products have a considerable export potential. The magnesium hydroxide and oxide, currently produced at the enterprise, are being tested at plants producing incombustible compositions, fuel oil additives, and catalytic agents in foreign countries, including the USA, India, and Denmark. Several large contracts on supply of magnesium hydroxide and oxide to Asian markets have already been executed, and about 1,500&nbsp;tons have been shipped.</p> <p>&ldquo;Having visited the NikoMag site, I was greatly impressed by the highest technological level of production. As of today, the production plant in Volgograd is the most advanced in the world in terms of used engineering solutions, process configuration and management. Following the negotiations, a <nobr>long-term</nobr> contract was signed on supply of NikoMag magnesium hydroxide and oxide to the Chinese market. Considering the excellent quality level, I think highly of prospects for the <nobr>Russian-made</nobr> products to enter Asian markets,&rdquo; said Mr. <strong>Yan Li</strong>, General Director of SINOPEC International Company Rus LLC.</p> <p>&ldquo;One of the success factors for this project is the effective choice of the niche, where the Company was able to propose a high quality product for a competitive price. Initially, we focused on it since we believe that the medium capacity chemistry sector in the Russian Federation has a very high potential and very high level of competitive capabilities on the global market. However, despite of strong fundamental indexes and availability of raw material base, it has been significantly undercapitalized recently; therefore, Russia imports chemical products for over $30&nbsp;bln at the moment. Subsequently, we expect emergence of attractive new projects and activation of strategic players in this area,&rdquo; pointed Mr. <strong>Dmitry Pimkin, </strong>Managing Director of Management Company RUSNANO LLC.</p> Mon, 1 Aug 2016 12:00:00 +0300 “This Thought Seems to Me Crazy Enough to Discuss It”. Anatoly Chubais about Fundamental Trends of Human Development. Speech at 13th STS Forum, Kyoto, Japan <p><strong>Dear Chairmen, esteemed colleagues!</strong></p> <p>My short speech on sustainable development I will try to divide in two parts: first is about the digital world and another on material world. I believe, sustainable development cannot be understood without understanding those two parts of the modern technological revolution. Certainly, I&rsquo;ll not pretend for comprehensive analysis, but just for snatching out single trend in each of them.</p> <p>Digital part, the ICT, is huge and comprehensive. Probably the most frequently discussed here is the topic of self-driving. Self-driving cars, self-driving tracks, self-driving ships, trains, helicopters, planes. What does it means in reality? That the ICT start to be able to operate in a very specific sectors of high human responsibility. I would say even more: on the previous stage of the ICT revolution computer helped human, but now it starts to substitute human. Reminds industrial revolution here, when machines, mechanisms, engines start to help and then substitute workers in what they were doing. But in that time, in time of industrial revolution mechanisms substitute human in physical capacity, and now it starts to substitute human in intellectual capacity.</p> <p>This fundamental deepness on interference of ICT in human activities will have strong and fundamental outcomes on sustainability. In this context we are discussing a robotization, we are discussing a labor market, we are discussing a rate of unemployment, etc. But I want to ask myself, what will be the next sector of human activity, what will be the next occupation, which can be substituted by the computer, by the ICT?</p> <p>Speaking about self-driving cars, I said that this is the sector of decision making with very high responsibility. So what next? What is the next sector of decision making with high responsibility? Being a manager myself, maybe the next sector where computer will start to substitute human will be&hellip; management?</p> <p>I don&rsquo;t think I am speaking about the years, but may be about the decades. Management, as we all know, is very comprehensive and diversified type of occupation, so maybe there are some less sophisticated management levels will be substituted first, and then stage by stage it will go further. If that&rsquo;s true, maybe the next era coming and we will call it &ldquo;Demanagerization&rdquo;? If we are speaking now about unmanned driven vehicles, why we she&rsquo;ll not speak about unmannedmanaged companies? Why not think about the next stage of ICT revolution which one may call &ldquo;demanagerization of human activity&rdquo;. For me this idea sounds crazy enough to be discussed here.</p> <p>That&rsquo;s the possible trend in digital part of sustainable development.</p> <p>As we come to the material part of the sustainable development, one word coming to my mind is the word suggested by famous economist, philosopher, and writer Vaclav Smil: in his recent book he suggested the term &ldquo;Dematerialization&rdquo;. If this term meaning would be decline of global material and energy demand, based on new materials with upgraded physical, mechanical, electrical properties, it may present fundamental trend in material world.</p> <p>On the previous STS Forum I was privileged to speak here about the nanotechnology, about nano-augmented materials. It is well known that if some nanoparticles, like carbon nanotubes, will be added in proportion less than 1%, to the plastic, cement and metal, they will strongly affect final material mechanical, physical and electric property. That is what we are doing in Russia. And one of our companies&mdash;OCSiAl&mdash;which is able to produce Single Wall Carbon Nanotubes in industrial scale technology step by step started to develop this market. So we are currently working with 5 of top 10 manufactures of lithium-ion batteries (increasing life-cycle of lithium-ion batteries), elastomer producer (making elastomer electrically conductive), with 8 of top 10 paintings and coating manufactures, with the drone manufactures, with the global chemical companies, with transparent conductive film producers, car and aircraft producers. All these huge markets are start to open stage by stage just last year. Situation strongly changed this year versus what I was able to speak about here last year. In the year 2016 we are tripling production and the sales of the company. And if we commissioned last year first in the world the 5-tonn of SWCNT reactor, now we are building the next with the 50-tonn capacity SWCNT reactor. Why? Because we believe, there is something that may really make basic material much lighter, much stronger, to reduce the amount of materials, to save energy and that will generate fundamental positive impact on the sustainability. There are three basic materials the human designed world consist from&mdash;metal, cement and plastic. If we will be able to produce them lighter and stronger, that is something what can bring strong upgrade on sustainability in a global sense.</p> <p>Am I wrong or am I right speaking about the demanagerization? That&rsquo;s the part where I just want to be provocative, following the instruction of our chairman. When I speak about dematerialization&mdash;new materials, nano-augmented materials&mdash;I&rsquo;ve tried to go from hypothesis to facts and forecasts. That is something what we work on and I hope we will be able to share with scientists, business leaders, politicians, anybody of the audience. Anyhow, the trends for demanagerization in digital world and for dematerialization in material world may become point for discussion on this forum.</p> <h5><a href="">Текст выступления Анатолия Чубайса на 13-м Международном форуме науки и&nbsp;технологии в&nbsp;обществе (STS&nbsp;Forum) в&nbsp;Киото, Япония</a></h5> Fri, 7 Oct 2016 12:00:00 +0300 Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout <ul> <li><em>First Immunotherapeutic Candidate to Leverage Selecta&rsquo;s Proprietary Synthetic Vaccine Particle (SVP&trade;) Platform</em></li> <li><em>SEL-212 Targeting Unmet Needs of Chronic Refractory and Tophaceous Gout Patients</em></li> <li><em>Initial Phase 2 Trial Results Expected in First Half of 2017</em></li></ul> <p>Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company&rsquo;s lead proprietary immunotherapeutic product candidate for the treatment of chronic gout in patients refractory to conventional therapy. This trial will assess the safety, tolerability and clinical activity of SEL-212, a combination product candidate consisting of pegsiticase (pegylated uricase) and SVP-Rapamycin. SEL-212 is designed to be the first non-immunogenic enzyme therapy for gout. Initial results from this trial are expected in the first half of 2017.</p> <p>&ldquo;SEL-212 has the potential to address the large unmet need of severe gout patients, who are currently lacking effective treatment options. By lowering serum uric acid levels and total body uric acid burden with multiple doses of SEL-212 covering up to 6 months of treatment, SEL-212 is designed to eliminate inflammatory deposits that cause debilitating pain and often serious damage to joints and organs,&rdquo; said&nbsp;<strong>Earl Sands</strong>, M.D., Selecta&rsquo;s Chief Medical Officer. &ldquo;The initiation of this trial marks an important advancement for our Synthetic Vaccine Particles (SVP) immunotherapeutic platform, which has the potential to enable and enhance a large number of biologic therapies including enzyme therapies, gene therapies and biologic cancer treatments by antigen-specific mitigation of undesired immune responses such as neutralizing antibodies.&rdquo;</p> <p>This Phase 2 clinical trial of SEL-212 is being conducted at 15 centers in&nbsp;the United States&nbsp;and is expected to enroll more than 36 symptomatic gout patients with elevated uric acid levels. The primary and secondary endpoints of the trial include safety and tolerability of multiple doses of SEL-212, reduction of serum uric acid levels and mitigation of anti-drug antibodies (ADAs). Exploratory endpoints include measurement of uric acid deposits by Dual Energy Computed Tomography (DECT) imaging. Multiple dose treatment with SEL-212 has the potential to significantly lower total uric acid crystal burden in joints and tissues, which cannot be effectively or rapidly achieved by oral gout therapy. The removal of the uric acid crystal deposits is expected to reduce overall inflammation and the frequency of debilitating gout flares.&nbsp;&nbsp;</p> <p>SEL-212 exemplifies Selecta&rsquo;s strategy to combine its SVP-Rapamycin platform with targeted biologics that require repeat administration to prevent the formation of ADAs. Undesired immune responses such as ADAs are a common complication with biologics including enzyme therapies, gene therapies, and cancer treatments. Application of the SVP platform may yield a pipeline of products with improved therapeutic benefit resulting from the reduction of unwanted immune responses.&nbsp;Selectaaims to advance a series of programs, including novel gene therapy products.</p> <h3>Phase 1 Data to be Presented&nbsp;December 7-8, 2016</h3> <p>In the Phase 1 clinical program of SEL-212, active and generally well-tolerated doses of pegsiticase and SVP-Rapamycin were identified in two single ascending dose trials with more than 75 patients. SVP-Rapamycin prevented the formation of ADAs and enabled pegsiticase to maintain sustained control of serum uric acid levels for at least 30 days after a single dose.</p> <p>On&nbsp;Wednesday, December 7, 2016&nbsp;at the 11th Annual Immunization and Vaccine Summit (IMVACS) in&nbsp;Boston, MA,&nbsp;Selecta&nbsp;will present results from this Phase 1 program. These results will also be discussed on a live conference call and webcast on&nbsp;Thursday, December 8, 2016&nbsp;at&nbsp;8:30 a.m. ET.</p> Fri, 28 Oct 2016 12:00:00 +0300 RUSNANO and KuibyshevAzot Start an Energy-efficient Caprolactam Production <p>KuibyshevAzot finished the large-scale project for modernization of caprolactam production (used for production of nylon and nylon-based products&mdash;industrial yarn and fabrics) based on advanced technologies with the use of nanostructured catalysts. Total investments in the project, which is being implemented in cooperation with RUSNANO, amounted to RUB 9.8 bln, including the RUSNANO co-funding in the amount of RUB 1.25 bln.</p> <div class="img"><img alt="RUSNANO and KuibyshevAzot start an energy-efficient caprolactam production" src="/upload/images/news/2016-08-26_KuibyshevAzot_700.jpg" /> <p>RUSNANO and KuibyshevAzot start an energy-efficient caprolactam production</p></div> <p>The Governor of the Samara Region <strong>Nikolai Merkushkin</strong>, the General Director of KuibyshevAzot JSC <strong>Alexander Gerasimenko</strong> and the Chairman of the Executive Board of RUSNANO MC <strong>Anatoly Chubais</strong> took part in the production launch ceremony.</p> <p>The Dutch group Royal DSM N.V., the global leader in development and production of high-technology materials and chemicals, made a technology transfer within the framework of the project: nanostructured catalysts are used in a number of key caprolactam synthesis processes. The implementation of know-how reduced the final production cost by 12%. The RUSNANO investments allowed increasing KuibyshevAzot&rsquo;s caprolactam production capacity from 190 to 210 thousand tonnes per year, and later&mdash;to 260 thousand tonnes per year.</p> <p>Construction and launch of the energy-efficient caprolactam production will allow the company to grow the production of its derivatives: polyamide-6 (nylon), industrial and filament yarns, cord fabric (used to make fiber glass). The project is among the Volga Federal District priorities.</p> <p>The project implementation will allow lowering the consumption of fuel gas (by 2.4 mln m<sup>3</sup> per year) and electric energy (3.2 MW per year), as well as reducing greenhouse gas emissions by 200 thousand tonnes per year, and incinerable wastes by 21%.</p> <p>KuibyshevAzot is in the top ten of national nitrogen industry plants and is the leader of the caprolactam and polyamide-6 production in the CIS and Eastern Europe. The company also produces 5% of all Russian fertilizers. KuibyshevAzot carries out operations in two main areas: caprolactam and its derivatives (polyamide-6, industrial and filament polyamide yarns, cord fabric, engineering plastics) and ammonia and nitrogen fertilizers (carbamide, ammonium nitrate, ammonium sulfate).</p> <p>&ldquo;Cooperation between RUSNANO and DSM facilitates the realization of our strategic plans on consolidation of leading positions on the caprolactam and polyamide markets and expansion of processing of these products within Russia. Utilization of nanotechnologies and technologies of leading global licensers will allow us to increase operating efficiency and competitiveness of the plant,&rdquo; said the General Director of the KuibyshevAzot JSC <strong>Alexander Gerasimenko</strong>.</p> <p>&ldquo;I think this is a one hundred percent example of real private ownership and real technology entrepreneurship. It is a case where the owners treat their business like a real lifetime work. The work that delivers impressive results not only for the plant itself, not only for the region, but for the whole country. I honestly believe that launches of this scale are a step forward for the entire national chemical industry. And I&rsquo;m simply proud that we have partners of such class. They are real partners in every sense of the word, most notably from the standpoint of competence in engineering, finances, and even simple human reliability,&rdquo; noted the Chairman of the Executive Board of RUSNANO MC <strong>Anatoly Chubais</strong>.</p> Fri, 26 Aug 2016 12:00:00 +0300 NeoPhotonics Corporation (NYSE: NPTN), a RUSNANO Portfolio Company, Launches Production in Moscow <p>NeoPhotonics Corporation a leading international designer and manufacturer of advanced hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks has launched manufacturing production operations at Technopolis Moscow. The opening ceremony was attended by the Russian Deputy Prime Minister <strong>Arkady Dvorkovich</strong> and the Chairman of the Executive Board of RUSNANO <strong>Anatoly Chubais</strong>.</p> <p>NeoPhotonics products enable cost-effective, high-speed data transmission and efficient allocation of bandwidth over communications networks.&nbsp; These optical modules are used to provide rapid data exchange in digital video, multimedia, music, video-conferencing, HD-TV and social networks.</p> <div class="img"><img alt="" src="" /> <p>NeoPhotonics Corporation (NYSE: NPTN), a RUSNANO Portfolio Company, launches production in Moscow</p> </div> <p>NeoPhotonics maintains headquarters in San Jose, California, USA and operates ISO 9001:2000 certified engineering and manufacturing facilities in Silicon Valley, USA, in Japan and in China.&nbsp; The company employs approximately 2500&nbsp;people worldwide.</p> <p>The company is investing up to $30&nbsp;million in its Russian production facility, creating 45 jobs including&nbsp;10 R&amp;D specialists and more than 30 jobs in manufacturing. NeoPhotonics established sales and R&amp;D offices in Moscow in May 2013 to serve customers from Russia and Eastern Europe.</p> <p>RUSNANO&rsquo;s investments in NeoPhotonics have created the first local, vertically integrated manufacturer of optical network components for Russian telecommunication equipment producers. The company will manufacture splitters (passive network devices that facilitates distribution of optical communications signals) in clean rooms at Technopolis Moscow. Russian demand for these devices was previously met entirely by imported products. This initial range of finished products is expected to be expanded in the future.</p> <p>The first production splitters were produced at the new facility in June 2015 and were subsequently used to support substantial technical qualifications and certification by customers in Russia and abroad. Customers are expected to include the leading Russian telecom provider, Rostelecom.</p> <p>All necessary agreements giving the Russian facility access to the NeoPhotonics technology platform (know-how and patents) will be concluded before the end of 2015. The agreements cover almost 60&nbsp;patented technology families for the production of a broad range of planar optical components for communications networks and includes access to the company&rsquo;s deep technology base enabling all stages of production of these and other devices.&nbsp;</p> <h3>Technical information</h3> <p><strong>A Photonic Integrated Circuit</strong> (PIC) is a device that integrates multiple photonic functions within a chip-level device produced using wafer-based semiconductor methods and which can perform a variety of functions related to optical signal processing (usually in the visible and near-infrared waveband).</p> <p>PIC production technology is similar to the technology used in production of ordinary electronic integrated circuits: deposition of silicon oxide or other materials is used to create layers and lithography is used to pattern wafers. PICs can contain waveguide interconnectors, power dividers, optical amplifier combiners, optical modulators, filters, and optical detectors. Photonic integrated circuits have a multitude of uses, but their main application as pursued by NeoPhotonics is in fiber-optic communication.</p> <p>PICs can be used to produce optical systems that are more compact and productive than systems based on discrete optical components. They are also capable of integration with electronic circuits for miniaturization of multifunctional electro-optical systems and devices.</p> <p>Optical splitters, which split the energy flow passing through an optic fiber, are among the highest volume devices produced using PIC technology. Optical splitters are passive devices, as they do not require their own energy supply in order to function.</p> <p>Optical splitters make it possible to transmit a signal to multiple recipients via a single fiber, reducing the construction cost of fiber-optic communication lines and opening the way for development of passive optical networks.</p> <p>There are currently two main types of optical splitters, distinguished by their production technologies: the planar lightwave circuit splitter, and the fused biconic taper splitter.</p> <p>The first is produced by chemical deposition of layers of optical material onto a wafer surface, such as quartz. At a certain point in the process a planar light pipe with the required configuration and optical density is etched through a mask. The light pipe is situated between the layers of optical material and acts as a core, transmitting the optical signal power. The effective result is a crystal or microchip composed of a quartz wafer and optical materials, enabling equal division of power via a Y-shaped splitter.</p> Fri, 11 Dec 2015 12:00:00 +0300